European Chemical Bulletin 9. by unknown
Cu-containing biomedical glasses             Section B-Research paper 
Eur. Chem. Bull. 2020, 9(1), 1-5    http://dx.doi.org/10.17628/ecb.2020.9.1-5 1 
THE EFFECTS OF ADDITION OF COPPER ON 
THE STRUCTURE AND ANTIBACTERIAL 
PROPERTIES OF BIOMEDICAL GLASSES 
Leyla Mojtabavi[a] and Amir Razavi[a]* 
 
Keywords: Biomedical glasses, copper, structure, XPS, antibacterial. 
The properties  of 3 and 6 mol % copper-containing bioactive glasses have been evaluated. The structure of the doped glass has been 
studied by X-ray diffraction (XRD), X-ray photoelectron survey (XPS), high-resolution scans and NMR spectroscopy. The results indicated 
that copper acts as a network modifier in the glass composition and copper-containing glasses show a less connected microstructure. 
Differential Thermal Analysis (DTA) showed that the copper addition in the glass lowers the glass transition temperature. Antibacterial 
studies showed that doping with copper enhances the antibacterial effect of the bioglass. 
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INTRODUCTION 
Bioglass®, also known as 45S5 glass, was first discovered 
by Larry Hench in the late 1960s in order to develop a 
material to fill bone voids without being rejected by the 
body.1 The initial 45S5 Bioglass® that was introduced by 
Hench was a silicate-based glass with a composition of 
45SiO2-24.5Na2O-24.5CaO-6P2O5 in weight percent.2 Early 
studies on this composition showed its capacity to form a 
chemical bond with living tissue.3 As a biodegradable 
material, the bioglass degrades slowly in an aqueous 
solution and stimulates new bone formation and growth 
through a chemical bond to the existing bone tissue.4 The 
dissolution of the glass and formation of the calcium 
phosphate layer on the surface of glass initiates the 
osteogenesis mechanism. Besides, the release of dissolution 
products from the glass into surrounding physiological 
solutions can provide therapeutic effects to adjacent tissue.5  
In the past few years, different compositions of bioactive 
glasses have been developed to improve the properties and 
take full advantage of these glasses for biomedical 
applications. The bioactive glasses have been used in dental 
applications, applied as bioactive coatings on the surface of 
metal implants, used as bioactive components of composites 
and have been made into synthetic bone scaffolds.2,3, 6-8 The 
diversity of their applications comes from the glass 
composition and how the incorporation of new elements can 
modify it and therefore changing the glass structure.2  
The atomic structure of the glass significantly affects its 
properties and in particular, the bioactivity and degradation 
rate, which directly influences the formation of calcium 
phosphate surface layer and cell viability.9 The key 
compositional factor in the determination of the bioactivity 
of these glasses is the SiO2 content.10 The bioactive glass 
composition consists of relatively low amounts of silica and 
high concentrations of network modifiers such as Ca and Na 
to facilitate its dissolution in the physiological solutions.8,10 
The structure of bioactive glasses can be described in the 
same way as other silicate glasses, which have been well 
characterized in terms of the arrangement of the SiO4 
tetrahedron coordination.11 The number of tetrahedrons 
determines the size of the ring used to characterize the 
network. The structure of pure SiO2 consists of a three-
dimensional network of SiO4 tetrahedra, and each 
tetrahedron is associated with bridging oxygen in the 
structure, through Si-O-Si bonding.12 The addition of 
network modifying elements disrupt the linkage of SiO4 
tetrahedra and creates non-bridging oxygens.13 As a result of 
incorporation of modifier ions, the disrupted glass network 
is now prone to hydrolysis in aqueous solutions, which is a 
critical step for the bioactivity of glass.5  
Since the introduction of bioactive glass by Hench, a wide 
variety of chemical modifications have been proposed by 
the incorporation of different elements in the glass. Some of 
the ubiquitous elements are Zn, Ti, and Sr.14,15 These 
elements have been added to the glass composition to 
improve its physical, mechanical and biological 
behaviour.9,16 In this work, we have incorporated copper in 
bioactive glass composition. Copper is a 
monovalent/divalent cation acting as a network-modifier in 
the glass structure.17 The addition of CuO at the expense of 
SiO2 can make the glass composition more soluble in the 
physiological solution, which in turn can enhance the 
bioactivity.  Irrespective of this role, copper may be 
beneficial to the biological properties associated with the 
resultant material as there are numerous reports on the 
positive antibacterial response associated with the use of 
copper.18,19  
The main purpose of this study is to modify the glass 
composition with the incorporation of copper in the glass 
and to determine its structural effects on the glass network. 
Further, we aim to investigate any changes occurring in the 
antibacterial efficacy of the glass as a result of copper 
addition. 
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EXPERIMENTAL 
Glass synthesis 
Three different glass powders were synthesized, a control 
and two copper-containing glasses. The control glass (BG) 
was synthesized based on a SiO2-CaO-Na2O-P2O5 
composition. The copper-containing glasses contain 3 and 6 
mol % of CuO at the expense of SiO2 (Table 1). The 
analytical grade reagents of SiO2, CuO, CaCO3, Na2CO3, 
NH4H2PO4 were mixed and milled for 30 min. The glass 
batch was then dried at 110 °C for 1 h and melted at 
1400 °C for 5 h in a platinum crucible and shock quenched 
in water.  
Table 1. Glass compositions (mol %) where SiO2 is substituted by 
CuO. 
Bioglass SiO2 CaO Na2O P2O5 CuO 
BG 55 20 20 5 0 
BG-3Cu 52 20 20 5 3 
BG-6Cu 49 20 20 5 6 
X-Ray Diffraction 
Synthesized glass powders were analyzed for their 
diffraction patterns using X-Ray Diffractometer (Shimadzu 
XRD-6100X) at 40 kV and 30 mA utilizing CuKa radiation. 
The range of angles was from 10° to 60°, at a step size of 
0.03° and step time of 10 s. 
Differential Thermal Analysis 
Differential Thermal Analysis (DTA) experiments were 
performed using an SDT Q600 DTA instrument. Around 25 
mg of each of the glass powders were loaded in platinum 
pans, where one empty platinum pan was also used as a 
reference. DTA curves were collected in air from 25 °C to 
1200 °C at the heating rate of 10 °C min-1. 
X-Ray Photoelectron Spectroscopy  
X-Ray photoelectron spectroscopy (XPS) was performed 
using a VG-Microtech ESCA-2000 system with AlKa 
source (hυ = 1486.6 eV) at the output of 25.5 W. Before the 
sample loading, the glass powders were first kept in a 
vacuum oven at 90 °C for 30 min to dry the powders. 
During the test, the vacuum in the analysis chamber of the 
instrument was in the range of10-9–10-10 mBar. Survey scans 
and high-resolution spectra of glass powders were collected, 
and the binding energies referenced to the C1s at 284.6 eV. 
Magic Angle Spinning Nuclear Magnetic Resonance (MAS-
NMR) 
MAS-NMR was carried out on powdered glass samples 
using a DSX-200 FT-NMR. The measurements were 
conducted at a frequency of 39.77 MHz, with the spinning 
rate at the magic angle of 5 kHz for 29Si with a recycle time 
of 2.0 s. The reference material used to measure the 
chemical shift was tetramethylsilane (TMS). 
Antibacterial Agar Diffusion 
The antibacterial efficacy of the glasses was tested using 
the agar diffusion test method. First, glass disks of the 
synthesized powders were prepared and kept under UV for 4 
hours for sterilization. Bacteria were grown aerobically in 
liquid broth at 37 °C for 48 h. Glass disks were placed in 
petri-dish covered with bacterial agar. The agar plates were 
then inoculated with the bacteria solution using a sterile 
swab and kept in the incubator for 24 h at 37 °C. After 24 h, 
the samples were evaluated for their inhibition zone by 
measuring the size of the zone from the edge of the disk to 
the end of the inhibition zone. 
RESULTS AND DISCUSSION 
In this study, a series of bioactive glass compositions were 
synthesized. BG is a bioactive control glass composed of 
SiO2, CaO, Na2O, and P2O5. BG-3Cu and BG-6Cu glasses 
contain incremental amounts of 3 and 6 mol % of CuO at 
the expense of SiO2. The specific compositions are shown in 
table 1. 
The initial characterization on glasses was to generate 
XRD patterns to identify if any crystalline phases were 
present in the glasses. XRD was performed on each glass 
composition (BG, BG-3Cu, and BG-6Cu), and results are 
presented in Figure 1. All three glasses show the 
characteristic amorphous curve for the silicate glasses at 
around 20 to 30 degrees. The amorphous hump arises from 
the glasses having no long-range atomic order in their 
molecular arrangement. The results from the diffractograms 
show that the glasses used for this study were predominantly 
amorphous in structure. 
 
 
 
 
 
 
 
 
Figure 1. X-ray diffractograms of amorphous glass powders of BG, 
BG-3Cu, and BG-6Cu. 
DTA was employed to measure the glass transition 
temperature (Tg), and the glass crystallization temperature 
(Tc), as a function of CuO addition. Figure 2 shows the 
DTA profiles of the glass series. The Tg of BG was found to 
be 646 °C, and the only Tc started at 936 °C. The Tg of BG-
3Cu and BG-6Cu glasses were found to be at 611 °C and 
590 °C, respectively. BG-3Cu showed two separate 
crystallization exotherm starting at 752 °C and 864 °C.  
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However, BG-6Cu had only one crystallization exotherm 
starting at 901 °C. Thus, it can be concluded that the CuO 
incorporation in the glass structure, shifts the glass transition 
to lower temperatures. Tg represents the temperature at 
which the glass begins the transformation from a solid 
material to a supercooled viscous liquid. Below Tg, the 
bonding in amorphous glass particles remains in a solid-
state, however, as the temperature increases, the bonding 
within the glass becomes more mobile where the materials 
behave more like a liquid. Tg is a valuable material property 
as it represents the upper-temperature limit at which the 
glass can be used. In this case, Tg establishes the network 
disruption of the glass, where a more disrupted glass 
network has a lower Tg. Therefore, DTA is a useful 
technique, which can be used to determine if any differences 
in the glass structure exist between the glasses as a function 
of temperature. Preliminary analysis of the glass structure 
using DTA, suggests that the CuO addition decreases the 
network connectivity and hence increases its disruption. 
This was further investigated by XPS and NMR studies.  
 
 
 
 
 
 
 
 
 
Figure 2. DTA profiles of BG, BG-3Cu, and BG-6Cu glasses.  
 
 
 
 
 
 
 
 
 
 
Figure 3. XPS survey scans of BG, BG-3Cu, and BG-6Cu glasses. 
Compositional analysis of each glass was then determined 
using XPS survey scans, as shown in Figure 3. The survey 
scan of BG contains Na, O, Ca, P, and Si, with minor traces 
of carbon (C). Both BG-3Cu and BG-6Cu glasses show the 
presence of Na, O, Cu, Ca, P, and Si with minor traces of 
carbon (C) as well, which corresponds with initial glass 
batch composition as shown in table 1. XPS survey scans 
were used to confirm the glass compositions and to find any 
possible contamination within the samples. High-resolution 
XPS was conducted on glasses to study the structure of glass 
as a function of CuO addition. The XPS O1s signals of glass 
series are shown in Figure 4. There is a compositional 
dependence on the binding energy of the O1s spectra of 
glasses when CuO is introduced in the composition. The 
peak for the control BG glass is cantered at 532.93 eV. For 
the copper-containing glasses, the O1s binding energies 
were found to be at 532.71, and 532.59 eV for BG-3Cu, and 
BG-6Cu, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. XPS O1s spectra of BG, BG-3Cu, and BG-6Cu glasses. 
As can be seen from Figure 4, the incorporation of the Cu 
at the expense of Si shifts the O1s binding energy to lower 
values.  Within the structure of oxide glasses, different 
oxygen species are present, as oxygen ions in the glass have 
different types of chemical bonding.20 The bonding 
environment of the oxygen ions can be studied by analyzing 
the O1s spectrum of the glass. Therefore, XPS O1s is a very 
useful technique to study the contribution of bridging to 
non-bridging oxygens in the glass.21 The lower binding 
energy peak of the O1s spectra is attributed to non-bridging 
oxygens, whereas the higher binding energy peak represents 
the bridging oxygens. The shift of the binding energies to 
lower values within the structure of copper glasses indicates 
an increase in the number of non-bridging oxygen at the 
expense of bridging oxygens.21 This effect is suggesting that 
the Cu is acting as a network modifier in the glass by 
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breaking the Si-O-Si bonds and replacing them with Si-O-
NBO. This is in agreement with the glass transition 
temperature studies observed with DTA. Glasses were 
further analyzed for their structure with 29Si MAS-NMR.  
 
 
 
 
 
 
 
 
Figure 5. 29Si MAS-NMR spectra of glass series.  
MAS-NMR was employed to analyze the structure of the 
glass series. Figure 5 shows the 29Si MAS-NMR spectra of 
the glass series, as SiO2 is the network former in the glass 
composition.  The chemical shift indicates the local 
environment around the silicon atom. The silicon spectra in 
these glasses predominantly show a large, broad peak at 
around -75 to -105 ppm. The chemical shift in a four-
coordinate silicon state is between –60 and –120 ppm.22 The 
chemical shift of the spectra in the glass depends on the 
percentage of non-bridging, and bridging oxygens bound to 
the silicon. Increasing the number of non-bridging oxygens 
will increase the shielding of the nucleus of the atom, so the 
peak shifts to the positive direction. However, increasing the 
number of bridging oxygens moves the peak in a negative 
direction due to decreased shielding.23  
The Q-structure of the glass relates to the number of BOs 
associated with the silicon atom. A silicon atom with 4-BOs 
can be assigned a Q-structure of Q4, 3-BOs assumes a Q3-
structure, 2-BOs assumes a Q2-structure etc.24 MAS-NMR 
can be used to calculate the chemical shift position for 
identifying the Q-structure of silica glass. Chemical shifts 
have been identified at >-78ppm for Q1, -80 ppm for Q2, -
90ppm for Q3 and -110ppm for Q4.22 The MAS-NMR 
spectra of the glasses tested in this work indicate 
predominant Q3/Q2 structures due to the chemical shift 
occurring mostly between -85 and -95 ppm. However, the 
broadness of the peaks suggests that all Q-structures may be 
present in the glass. For BG, a high degree of asymmetry 
exists within the Q4 region of the spectra. The peaks 
obtained from the MAS-NMR spectra of the BG, BG-3Cu, 
and BG-6Cu glasses are cantered at -91 ppm, -89 ppm and -
88 ppm, respectively. It is evident with copper-containing 
glasses that their broad spectra predominantly occur at 
Q3structure. However, a slight shift is happening towards 
the Q2 region of the spectra as they move more towards a 
positive direction. This suggests that copper glasses may 
contain higher quantities of Q2 structures and therefore 
contain a higher number of non-bridging oxygens compared 
to control.  
The results obtained from DTA, XPS and NMR spectra 
suggest that the control glass is more structurally defined 
than the copper-containing glasses. Incorporation of the 
copper in the glass disrupts the glass network by increasing 
the number of non-bridging oxygens, which indicates that 
CuO acting as a network modifier in this glass system. 
Understanding the distribution of Q-species is essential 
because the formation of non-bridging oxygens will affect 
glass solubility, which plays a critical role in the dissolution 
of the particle surface that initiates the bioactive sequence.25 
 
 
 
 
 
 
 
 
Figure 6. Antibacterial agar diffusion of BG, BG-3Cu, and BG-
6Cu glasses against E. coli and S. epidermis. 
One of the primary advantages of bioactive glass 
compositions is the ability to incorporate therapeutic ions to 
improve the antibacterial efficacy of the glass and, therefore, 
to reduce the infection risk.16 The antibacterial efficacy of 
the glass compositions was evaluated using agar diffusion 
testing method and against two common bacteria strains: 
aerobic Gram-positive coccus S. epidermis and aerobic 
Gram-negative, E. coli. Glass disks were placed within 
inoculated plated, cultured for 24 h, and then tested for their 
inhibition zones.  
The results from the agar diffusion test of the glass 
samples are presented in Figure 6. The copper-containing 
glasses are showing significantly higher antibacterial 
efficacy compared to control glass. No inhibition zone was 
detected for control glass against E. coli, however, for BG-
3Cu, and BG-6Cu glasses, 3 and 9 mm of inhibition zone 
was observed. Glasses showed better antibacterial properties 
against S. epidermis bacteria, with 2, 5 and 16 mm of 
inhibition zone for, respectively.  
From Figure 6, it is evident that the BG, BG-3Cu, and 
BG-6Cu glasses inhibition zones associated with the copper 
glasses increase with the copper concentration in the glass. 
The antibacterial mechanism of copper can be complex. 
However, previous studies suggest that copper ions disrupt 
the function of microbes by binding to proteins and enzymes 
in the microbes and therefore impede their activity. Using 
copper in the composition of the bioactive glasses can 
provide an alternative to antibiotics loaded biomaterials.18, 26 
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CONCLUSION 
The substitution of CuO for SiO2 was investigated to 
study the structural effects and antibacterial efficacy in the 
bioactive glass compositions. Results from DTA, XPS, and 
NMR indicated that the copper ions act as network 
modifiers in the glass structure. The addition of copper 
resulted in a higher number of non-bridging oxygens at the 
expense of birding-oxygen. This resulted in a more 
disrupted network in copper-containing glasses, which in 
turn could increase the solubility and bioactivity of the glass 
in physiological solutions. The results from the agar 
diffusion antibacterial test indicated significantly higher 
efficacy of copper-containing glasses, as potential 
alternatives for antibiotics in the biomedical glasses. 
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HEPES BUFFER MEDIATED SYNTHESIS OF 3,4-DIHYDRO-3,3-
DIMETHYL-9-ARYLACRIDIN-1-ONES  
Suchita S. Gadekar, [a] Suryakant B. Sapkal, [b] Balaji R. Madje [a]* 
 
Keywords: HEPES buffer; phenylacridin-1-ones; organocatalyst. 
One-pot three-component synthesis of 3,4-dihydro-3,3-dimethyl-9-phenylacridin-1(2H,9H,10H)-one derivatives has been described by the 
cyclocondensation of aromatic aldehydes, aromatic amines and dimedone in the presence of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) in ethanol at reflux condition. Besides buffering agent, HEPES as an organocatalyst has been used for the first time in 
multicomponent organic transformation and succeeded along with various merits of green chemistry practices. The reaction is mechanized 
by zwitterionic interactions between organocatalyst and reactants to form targeted molecules. 
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INTRODUCTION 
Nowadays, the time has come to expand the horizon of our 
conscious foresight about environmental consequences and its 
inequality in the world that leads to natural disasters. It is expected 
from all the chemists and co-workers while performing any 
chemical transformations in the laboratory. Therefore, chemists 
have to modify the protocols or keep control of it so that the 
developed methodology can help to protect human health and 
maintains the environment unaffected. Keeping these factors in 
view, it was thought worthiness to synthesize 3,4-dihydro-3,3-
dimethyl-9-phenylacridin-1-ones by means of buffer mediated 
organocatalyst with conventional techniques. In literature buffering 
activity of HEPES is widely utilized to maintain local pH of the 
biochemical, biological reactions and environmental studies, 1-3 for 
the synthesis of specific sized nanogold particles,4 detection of 
ATP in clinical applications,5 to study function characteristics of 
hemoglobin.6  
Beside this other various organocatalysts have been extensively 
used for the synthesis of different heterocyclic organic compounds 
through C-C and C-heteroatom bond formation reactions.7,8 The 
catalytic proficiency of an organocatalyst is quite significant and 
beneficent than biocatalysts and metal catalysts toward organic 
transformations. The mechanistic role of an organocatalyst for the 
initiation or the activation of the reactant molecule is either by 
providing or removing protons or electrons for the reacting 
species.9 
Our targeted molecule based on the acridine nucleus is very 
versatile in pharmacological behavior such as a wide range of 
anesthetic activity viz surface anesthesia, infiltration anesthesia, 
peripheral and spinal anesthesia, etc., antimalarial agent, antiseptic 
and anticancer agents.10,11 Other few literature reports reveled that 
acridine moiety shows antibacterial activity, antifungal activity,12 
antiproliferative activity13 and antioxidant.14 Because of the wide 
spectrum of medicinal activity chemists have attempted to 
synthesize acridine derivatives by several ways that have been 
discussed in the reported review and multi-step synthetic routes 
under different reaction conditions and use of various reagents by 
conventional and non-conventional as well.15 Some 
multicomponent methodologies have also been reported, like protic 
pyridinium ionic liquid,16 L-proline,17 nano ferrite18, etc. However, 
aspects of green chemistry need some more effort that could 
develop sustainable protocols.  
Therefore, we used HEPES buffering agent preferentially as an 
organocatalyst, which found to be smart and compatible in various 
reaction conditions with a variety of substrates and contributes a 
part of green chemistry. 
EXPERIMENTAL 
All the reagents and solvents were used for the reactions and 
column chromatography was purchased from HiMedia, Finechem, 
Spectrochem and Rankem chemical companies and used directly 
without further purification. The progress of the reactions was 
monitored by Thin Layer chromatography 60 F254 (TLC). 1H 
NMR spectra were recorded on 300 MHz FT-NMR spectrometer in 
CDCl3 as a solvent and chemical shifts were reported in parts per 
million (ppm) relative to tetramethylsilane (CH3)4Si. 
Experimental procedure for the preparation of 3,4-dihydro-
3,3-dimethyl-9-phenylacridin-1(2H,9H,10H)-one derivatives 
In the hard glass test tube benzaldehyde (0.221 g, 0.002 mol) and 
aniline (0.193 g, 0.002 mol ) and HEPES (40 mg) in 25 mL ethyl 
alcohol were stirred at reflux temperature for 30-35 minutes. To 
this solution, dimedone (0.290g, 0.002 mol) was added portion 
wise with continued stirring at same temperature. The progress of 
the reaction was monitored after interval of each half hour by TLC. 
The reaction is completed after specified period of time. After 
completion the reaction mixture was poured on crushed ice. The 
obtained solid was filtered, dried and purified by recrystallization 
in ethanol to yield a pure product. Similar procedure was applied 
for the synthesis of other derivatives. All compounds were 
characterized by spectroscopic analysis. 
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3,4-Dihydro-3,3-dimethyl-9-phenylacridin-1(2H,9H,10H)-one 
(4a) 
M. P. 170-172 °C; 1H NMR (CDCl3) δ ppm; of 10.12 (S, 1H, N-
H), 6.45 - 7.85 (m, 9H, Ar-H), 5.55 (S, 1H, C-H), 3.01 (q, 4H, 
CH2 ,J= 24.6), 1.75 (S,6H, CH3); MS m/z = 303.14; IR (KBr); v 
cm-1 3015 (N-H Str.), 2867 ( CH3 Str.),1715 (C=O Str.), 1399 
(C=C Str.). 
9-(4-Chlorophenyl)-3,4-dihydro-3,3-dimethylacridin-
1(2H,9H,10H)-one (4b) 
M. P. 167-169 °C; 1H NMR (CDCl3) δ ppm; of 9.98 (S, 1H, N-
H), 7.12 (d, 2H, Ar-H, J= 1.4), 7.30 (d, 2H, Ar-H, J= 8.10), 6.45 - 
6.99 (m, 4H, Ar-H), 4.75 (S, 1H, C-H), 2.67 (S, 4H, CH2), 1.15 
(S,6H, CH3); MS m/z = 337.17; IR (KBr); v cm-1 3109 (N-H Str.), 
3004 ( CH3 Str.),1778 (C=O Str.), 1429 (C=C Str.), 760 (C-Cl Str.). 
7-Chloro-3,4-dihydro-3,3-dimethyl-9-phenylacridin-
1(2H,9H,10H)-one (4c) 
M. P. 188-190 °C; 1H NMR (CDCl3) δ ppm; of 10.02 (S, 1H, N-
H), 7.82 (d, 2H, Ar-H, J= 1.9), 7.34 (S, 1H, Ar-H), 6.90 - 7.15 (m, 
5H, Ar-H), 4.96 (S, 1H, C-H), 3.07 (S, 4H, CH2), 2.15 (S,6H, 
CH3); MS m/z = 337.30; IR (KBr); v cm-1 3120 (N-H Str.), 3024 
( CH3 Str.),1790 (C=O Str.), 1429 (C=C Str.), 810 (C-Cl Str.). 
3,4-Dihydro-3,3-dimethyl-9-p-tolylacridin-1(2H,9H,10H)-one 
(4d) 
M. P. 199-201 °C; 1H NMR (CDCl3) δ ppm; of 9.42 (S, 1H, N-
H), 7.15 - 7.78 (m, 8H, Ar-H), 4.74 (S, 1H, C-H), 2.81 (q, 4H, 
CH2 ,J= 21.7), 1.75 (S,6H, CH3), 2.25 (S,3H, CH3); MS m/z = 
317.20; IR (KBr); v cm-1 2983 (N-H Str.), 2796 ( CH3 Str.),1648 
(C=O Str.), 1290 (C=C Str.). 
3,4-Dihydro-9-(4-hydroxy-3-methoxyphenyl)-3,3-
dimethylacridin-1(2H,9H,10H)-one (4e) 
M. P. 145-147 °C; 1H NMR (CDCl3) δ ppm; of 9.98 (S, 1H, N-
H), 7.12 (d, 2H, Ar-H, J= 1.4), 7.30 (d, 2H, Ar-H, J= 8.10), 6.45 - 
6.99 (m, 4H, Ar-H), 4.75 (S, 1H, C-H), 2.67 (S, 4H, CH2), 1.15 
(S,6H, CH3), 5.98 (S, 1H, O-H); MS m/z = 349.12; IR (KBr); v 
cm-1 3109 (N-H Str.), 3004 ( CH3 Str.),1778 (C=O Str.), 1429 
(C=C Str.), 760 (C-Cl Str.), 3358 (OH Str). 
3,4-Dihydro-3,3,7-trimethyl-9-phenylacridin-1(2H,9H,10H)-one 
(4f) 
M. P. 158-160 °C; 1H NMR (CDCl3) δ ppm; of 9.42 (S, 1H, N-
H), 7.15 - 7.78 (m, 8H, Ar-H), 4.74 (S, 1H, C-H), 2.81 (q, 4H, 
CH2 ,J= 21.7), 1.75 (S,6H, CH3), 2.05 (S,3H, CH3); MS m/z = 
317.28; IR (KBr); v cm-1 2983 (N-H Str.), 2796 ( CH3 Str.),1648 
(C=O Str.), 1290 (C=C Str.). 
3,4-Dihydro-3,3,7-trimethyl-9-(4-nitrophenyl)acridin-
1(2H,9H,10H)-one (4g) 
M. P. 197-199 °C; 1H NMR (CDCl3) δ ppm; of 10.95 (S, 1H, N-
H), 8.02 (d, 2H, Ar-H, J= 1.3), 7.94 (S, 1H, Ar-H), 7.30 (d, 2H, Ar-
H, J= 9.75), 7.09 (S, 1H, Ar-H), 5.60 (S, 1H, C-H), 2.51 (q, 4H, 
CH2 ,J= 24.6), 2.02 (S, 3H, CH3), 1.20 (S,6H, CH3); MS m/z = 
364.4; IR (KBr); v cm-1 3065 (N-H Str.), 2937 ( CH3 Str.), 1721 
(C=O Str.), 1520 (-NO2 Str.), 1461 (C=C Str.). 
9-(4-(Dimethylamino)phenyl)-3,4-dihydro-3,3-dimethylacridin-
1(2H,9H,10H)-one (4h) 
M. P. 160-162 °C; 1H NMR (CDCl3) δ ppm; of 9.82 (S, 1H, N-
H), 6.45 - 7.85 (m, 8H, Ar-H), 5.05 (S, 1H, C-H), 3.01 (q, 4H, 
CH2 ,J= 24.6), 1.75 (S,6H, CH3), 3.25 (S,6H, CH3); MS m/z = 
346.14; IR (KBr); v cm-1 3015 (N-H Str.), 2867 ( CH3 Str.),1715 
(C=O Str.), 1399 (C=C Str.), 1155 (C-N Str.). 
3,4-Dihydro-3,3,9-trimethylacridin-1(2H,9H,10H)-one (4i) 
M. P. 176-178 °C; 1H NMR (CDCl3) δ ppm; of 8.62 (S, 1H, N-
H), 6.45 - 7.85 (m, 4H, Ar-H), 3.95 (S, 1H, C-H), 2.71 (q, 4H, 
CH2 ,J= 24.6), 1.25 (S,6H, CH3), 1.45 (S,3H, CH3); MS m/z = 
241.10; IR (KBr); v cm-1 3015 (N-H Str.), 2867 ( C-H Str.),1715 
(C=O Str.), 1399 (C=C Str.). 
9-(Furan-2-yl)-3,4-dihydro-3,3-dimethylacridin-1(2H,9H,10H)-
one (4j) 
M. P. 120-122 °C; 1H NMR (CDCl3) δ ppm; of 4.22 (S, 1H, N-
H), 6.45 -6.85 (m, 7H, Ar-H), 4.77 (S, 1H, C-H), 4.01 (q, 4H, 
CH2 ,J= 24.6), 1.11 (S,6H, CH3); MS m/z = 293.14; IR (KBr); v 
cm-1 3110 (N-H Str.), 2967 ( C-H Str.),1615 (C=O Str.), 1400 
(C=C Str.). 
RESULTS AND DISCUSSION 
To take a broad view of an experimental procedure, we have 
optimized the reaction conditions by several methods, out of which 
few successful reports have been demonstrated here with this 
discussion. Previously, we fruitfully attempted to establish such 
conventional and non-conventional methods for the preparation of 
various heterocyclic compounds.19,20 
For the synthesis of 3,4-dihydro-3,3-dimethyl-9-phenylacridin-
1(2H,9H,10H)-one (4) initially, in the hard test tube we refluxed 
benzaldehyde (1), aniline (2) and dimedone (3) with constant 
stirring in the presence of HEPES as a organocatalyst in ethanol as 
a reaction medium (Scheme 1). 
 
 
 
 
Scheme 1. Synthesis of 3,4-dihydro-3,3-dimethyl-9-phenylacridin-
1(2H,9H,10H)-one. 
 
But we observed that it took a prolonged time (18 hrs) with less 
product yield. Then, we decided to optimize the reaction 
concerning catalyst concentration, reaction time and percent yield. 
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After several experimental attempts, we came to know that reaction 
proceeds to completion by proper sequential addition of reactant 
and catalyst. Accordingly, benzaldehyde, aniline and HEPES were 
refluxed for 30-35 minutes yellow coloration is observed in the 
reaction vessel, which indicates the formation of Schiff's base as an 
intermediate.
 
Table 1. Screening of solvents for model reaction (preparation of 
1). 
No. Solvent Time, h Yield, % 
1 Methanol 6.50 45 
2 Ethanol 3.00 79 
3 Isopropyl alcohol 5.50 60 
4 Aqueous alcohol (1:1) 11.50 40 
5 Acetone 5.50 60 
6 DCM 7.20 45 
7 Chloroform 6.00 50 
8 Ethyl acetate 6.20 50 
 
Later on, dimedone is added in that reaction vessel portion-wise 
under the same reaction condition that leads to the formation of the 
targeted product by cyclocondensation manner within the next 
couple of hours. To establish the optimized protocol, we examined 
different protic-non protic and polar-nonpolar solvents such as 
alcohols, aqueous alcohol, acetone, dichloromethane (DCM), 
chloroform, ethyl acetate, etc. (Table 1) and a stoichiometric study 
has also been completed (Table 2). 
Table 2. Effect of catalyst concentration on model reaction. 
After the successful screening of suitable solvent and 
stoichiometry determination for catalyst, it has been reported that 
synthesis of 3,4-dihydro-3,3-dimethyl-9-phenylacridin-
1(2H,9H,10H)-ones by the cyclocondensation of benzaldehyde, 
aniline and dimedone is in the presence of HEPES as an 
organocatalyst in ethanol as a reaction medium. 
 
To take a broad view, the set procedure has been implemented 
for various aldehydes and anilines to produce different derivatives 
of 3,4-dihydro-3,3-dimethyl-9-phenylacridin-1(2H,9H,10H)-one 
(Table 3). 
Table 3. HEPES catalyzed synthesis of 3,4-dihydro-3,3-dimethyl-
9-phenylacridin-1(2H,9H,10H)-one derivatives. 
Entry R/Aldehyde Rʹ/Amine Time, h Yield, % 
4a H H 3 79 
4b 4-Cl H 3 76 
4c H 4-Cl 3 71 
4d 4-CH3 H 3 78 
4e 4-OH, 3-OCH3 H 3 70 
4f H 3-CH3 3 72 
4g 3-NO2 4-CH3 3 69 
4h 4-N(CH3)2 H 3 80 
4i Acetaldehyde H 3 64 
4j Furfuraldehyde H 3 69 
During derivatization, it has been noted that aromatic aldehydes 
and anilines with different substitutions at different positions have 
been reacted smoothly with appreciable product yield. In 
conjunction with an output of the reaction in our hand, heterocyclic 
reactants also give a compatible yield of the product, whereas 
aliphatic aldehyde resulted in comparatively less yield and took 
more time for transformation. The formation of products was 
confirmed by their physical constant and structures were elucidated 
by spectroscopic analysis.
 
CONCLUSIONS 
We have developed a sustainable protocol, which will be the 
user-friendly synthetic route for pharmacodynamic 3,4-dihydro-
3,3-dimethyl-9-phenylacridin-1(2H,9H,10H)-one derivatives 
favored by buffering agent HEPES as a catalyst in ethyl alcohol. 
HEPES have a zwitterionic structure that drives successful 
interaction between reactants at near-neutral pH. This synthetic 
strategy also covers the advantages of one-pot multicomponent 
transformations, which will make this research work practical and 
economically feasible and provides foresight for sustainability.  
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Synthesis, characterization, antioxidant and antimicrobial activities of novel pyrazolines and phenylpyrazoline containing substituted 
pyridine and piperazine benzoisothiazole moieties have been reported. When these synthesized compounds were exposed for antioxidant 
screening, some among them exhibited prominent DPPH radical scavenging activity and superoxide radical (SOR) scavenging activity 
where ascorbic acid used as standard. During the antimicrobial screening compounds, some derivatives were found to be very active against 
Cryptococcus neoformans, which was supported on the basis of higher free binding energies with methionyl-tRNA synthetase. 
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INTRODUCTION 
Pyrazolines, a class of five-membered heterocycles, is 
recognized for never-ending research and development in 
terms of therapeutic potential. As a result, pyrazolines have 
become an obvious core of numerous drugs having diverse 
activities.1 The broad spectrum of activities shown by the 
pyrazolines encourages searchers to modify their structures 
by building with some biologically important heterocyclic 
compounds like alkyl, aromatic, heterocyclic rings and other 
groups at different positions on the ring which helps to 
create a novel class of desired compounds.  
Pyrazoline and its analogs act as significant pharmacies 
and synthons in the field of organic chemistry and drug 
designing. They are well-acknowledged for 
pharmacologically interesting heterocyclic systems through 
recent literature survey.2 Pyrazolines possess a wide range 
of biological properties such as anticancer,3-5 anti-
inflammatory,6 antibacterial,7 anti-depressive and 
anticonvulsant,8 antimicrobial,9 antinociceptives10 and 
enzyme inhibitors.11 Thus pyrazolines are well recognized 
for various biological activities.12,13 Hence, synthesis of new 
heterocycles bearing pyrazolines remains the core area of 
research. Numerous methods were developed for the 
synthesis of pyrazoline and their synthetic counterparts, 
among which the classical method involves cyclization of 
the Michael acceptor unit (chalcone) with hydrazine hydrate 
or phenylhydrazine in the presence of cyclizing agents like 
acetic acid or simple heating procedure.14  
Thus, considering the biological significance of 
pyrazolines and in continuation of our efforts in the 
development of biologically active entities;15-17 in the 
present work, we report the synthesis, characterization, 
antimicrobial and antioxidant activities of some novel 
pyrazolines bearing pyridine and benzoisothiazole 
containing piperazine moiety.  
The results of biological activities were supported by 
molecular docking studies. ADMET study was performed to 
know the drug-likeness and toxicity profile of the 
synthesized compounds. 
MATERIALS AND METHODS  
Melting points were recorded in an electrothermal melting 
point apparatus and were uncorrected. The consumption of 
starting material and formation of the products was 
monitored on silica precoated thin layer chromatography 
plate using 40 % ethyl acetate : n-hexane as the mobile 
phase. FTIR spectra were recorded using KBr pellets (100 
mg) on Shimadzu FT-IR spectrophotometer. 1H and 13C 
NMR spectra were recorded on Bruker 400 MHz 
spectrometer and chemical shifts were expressed in δ ppm 
with reference to tetramethylsilane (TMS) as the internal 
standard.  
In the antimicrobial activity, the zones of inhibition and 
the antioxidant activity performed spectrophotometrically 
were expressed as mean ± SD of three replicates. 
General procedure for the synthesis of pyrazolines 
A mixture of chalcone (0.7g, 0.16 mol) and hydrazine 
hydrate (1.0 mL) or phenylhydrazine in ethanol (1.0 mL) 
was stirred for 2 h at 25-35 oC. Sometimes heating at 45-50 
oC was required for dehydration. The precipitated solid was 
filtered off to get a crude product which was crystallized 
with hot ethanol to get pure white color material.  
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2-((4-(4,5-Dihydro-3-phenyl-1H-pyrazol-5-yl)-2-methoxyphen-
oxy)methyl)-3,4-dimethoxypyridine (1) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.89 (dd, J = 10.4 
& 10.8 Hz, 1H), 3.39 (dd, J = 10.4 & 10.8 Hz, 1H), 3.72 
(3H, s), 3.77 (3H, s),  3.90 (3H, s), 4.78 (t, 1H),  5.08 (s, 2H), 
6.85 (d, J = 8.4 Hz, 1H), 7.00 (s, 1H), 7.04 (d, J  =  8.4 Hz, 
1H), 7.14 (d, J  = 5.6 Hz, 1H),  7.31 (d, J = 6.8 Hz, 1H), 
7.37 (t, J  = 7.2 Hz, 2H) , 7.50 (s, 1H,  -NH), 7.61 (d, J  = 
7.6 Hz, 2H), 8.20 (d, J = 5.6 Hz, 1H); 13C NMR (101.3 MHz, 
CDCl3) δ ppm 41.2, 54.9, 55.2, 61.42, 62.58, 68.11, 107.65, 
109.61, 114.65, 116.4(2), 118.51, 118.94, 127.44, 130.21, 
134.70, 144.66, 145.79, 148.07, 149.85, 149.95, 154.16, 
157.61, 158.75; ESIMS  m/z 420.4 [M + H]+. 
2-(5-(4-((3,4-Dimethoxypyridin-2-yl)methoxy)-3-methoxyphe-
nyl)-4,5-dihydro-1H-pyrazol-3-yl)phenol (2) 
1H-NMR (400 MHz, DMSO-d6) δ ppm 3.07 (dd, J =10.8 
Hz & 11.2 Hz, 1H); 3.56 (dd, J = 10.4 Hz & 11.2 Hz, 1H); 
3.72  (s, 3H); 3.77 (s, 3H); 3.90 (s, 3H); 4.8 (t, 1H); 5.03 (s, 
2H); 6.87-6.91 (m, 2H); 7.03 (s, 1H); 7.07 (d, J = 8.4 Hz, 
1H); 7.15 (d, J  = 5.6 Hz, 1H); 7.22  (t, J = 8.0 Hz, 2H); 7.29 
(d, J =7.6 Hz, 1H); 8.21 (d, J = 5.6 Hz, 1H); 10.19 (s, 1H); 
11.18 (s, 1H); 13C NMR (101.3 MHz, CDCl3) δ ppm 41.51; 
55.59; 55.7; 61.4; 62.5; 68.1; 107.6; 109.6; 114.6; 116.4(2); 
118.5; 118.9; 127.4; 130.2; 134.7; 144.6; 145.7; 148.0; 
149.8; 149.9;154.1; 157.6; and 158.7; ): FT-IR (KBr) cm-1 
761, 825, 1163, 1224, 1352, 1496, 1591 & 1516; ESIMS  
m/z 436.4 [M + H]+. 
2-(5-(4-((3,4-Dimethoxypyridin-2-yl)methoxy)-3-methoxyphe-
nyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methylphenol (3) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.23 (s, 3H), 3.05 
(dd, J  = 10.8 & 11.2, 1H), 3.31 (dd, J  = 10.4 & 10.6, 1H), 
3.75 (s, 3H), 3.78 (s, 3H), 3.90 (s, 3H), 4.99 (t, 1H), 5.06 (s, 
2H), 6.45 (bs, 2H), 6.77 (d, J = 8.4 Hz, 1H), 6.95 (d, J  = 7.2 
Hz, 1H), 7.07 (d, J  = 7.6 Hz, 1H), 7.11-7.16 (m, 3H), 7.59 
(s, 1H), 8.22 (d, J  = 5.6 Hz, 1H); 13C NMR (101.3 MHz, 
CDCl3) δ ppm 20.69, 31.19, 55.69, 55.91, 61.55, 68.19, 
77.34, 107.74, 109.73, 113.95, 117.42, 118.54, 120.77, 
123.64, 130.70, 131.03, 133.18, 142.67, 144.82, 145.89, 
148.53, 149.87, 150.09, 154.14, 158.8; ESIMS  m/z 450.4 
[M+H]+. 
2-((4-(4,5-Dihydro-3-(2-methoxyphenyl)-1H-pyrazol-5-yl)-2-
methoxyphenoxy)methyl)-3,4-dimethoxypyridine (4) 
1H NMR (400 MHz, DMSO-d6)  δ ppm 2.91 (dd, J  = 10.8 
& 11.2 Hz, 1H), 3.38 (dd, J  = 10.4 & 10.8 Hz, 1H), 3.71 (s, 
3H), 3.74 (s, 3H),  3.75 (s, 3H), 3.87 (s, 3H), 4.69 (t, 1H), 
5.00 (s, 2H), 6.85 (d, J  = 7.2 Hz, 1H), 6.92 (t, 2H), 6.97 (s, 
1H), 7.02 (dd, J  = 5.2 & 4.4 Hz, 1H), 7.12 (d, J  = 5.6 Hz, 
1H), 7.27 (d, J  = 7.6 Hz, 1H), 7.30 (d, J =2.8 Hz, 1H), 7.62 
(d, J  = 7.6 Hz, 1H), 8.19 (d, J  = 5.6 Hz, 1H); ESIMS  m/z 
450.4 [M + H]+ . 
 
2-((4-(3-(4-Fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-
methoxyphenoxy)methyl)-3,4-dimethoxy pyridine (5) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.84 (dd, J  = 10.8 
& 10.8  Hz, 1H), 3.39 (dd, J  = 9.6.4 & 10.4 Hz, 1H), 3.71 (s, 
3H), 3.74 (s, 3H), 3.77 (s, 3H), 3.90 (s, 3H), 4.66 (t, 1H), 
5.08 (s, 2H), 6.88 (d, J  = 7.2 Hz, 1H), 6.92 (t, 2H), 6.97 (s, 
1H), 7.02 (dd, J  = 5.2 & 4.4 Hz, 1H), 7.11 (t, J  = 8.0 Hz, 
2H), 7.15 (d, J  = 5.6 Hz, 1H), 7.55 (dd, J  = 5.6 & 4.8 Hz, 
2H), 8.23 (d, J  = 5.6 Hz, 1H); 41.32, 55.76, 59.64, 64.17, 
71.99, 105.8, 109.51, 114.27, 115.29, 115.42, 118.44, 
126.15, 126.54, (127.48, 127.58  F-C) , 129.03, 129.06, 
135.56, 147.51, 148.75, 149.86, 150.11, 154.18, 161.55 (F-
C), 164.0 (F-C), 164.19; ESIMS  m/z 438.3 [M + H]+ . 
6-(5-(4-((3,4-Dimethoxypyridin-2-yl)methoxy)-3-methoxyphe-
nyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-benzo[b][1,4]oxazin-
3(4H)-one (6) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.79 (dd, J = 9.2 & 
9.6 Hz, 1H), 3.71 (s, 3H), 3.76 (s, 3H), 3.79 (dd, J = 10.8 & 
10.8 Hz, 1H), 3.90 (s, 3H), 4.59 (s, 2H), 4.75 (s, 2H) 5.02 (s, 
2H), 6.85 (d, J  = 7.2 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.95 
(s, 1H), 7.05 (d, J = 8.4 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 
7.14 (d, J = 5.6 Hz, 1H), 7.25 (s, 1H), 7.41 (s, 1H), 8.22 (d, 
J  = 5.6 Hz, 1H), 10.21 (s, 1H),  10.77 (s, 1H), 13C NMR 
(101.3 MHz, CDCl3)  δ ppm  41.55, 55.65, 55.78, 61.48, 
63.99, 67.16, 67.93, 107.70, 109.69, 113.04, 114.04, 116.57, 
118.49, 122.17, 126.57, 127.60, 135.39, 144.18, 144.67, 
145.77, 147.88, 149.79, 149.99, 150.73, 158.87, 165.57; FT-
IR (KBr) cm-1 1597, 1521, 1498, 1354, 1228, 1166, 828, 
767;  ESIMS  m/z 491.4 [M + H]+. 
2-((4-(4,5-Dihydro-3-phenyl-1H-pyrazol-5-yl)-2-methoxyphen-
oxy)methyl)-4-methoxy-3,5-dimethylpyridine (7) 
1H NMR (400 MHz, DMSO-d6) δ ppm  2.22 (s, 3H), 2.25 
(s, 3H), 2.89 (dd, J  = 10.4 & 10.8 Hz, 1H), 3.39 (dd, J  = 
10.4 & 10.8 Hz, 1H), 7.04 (d, J  = 8.4 Hz, 1H), 3.73 (s, 6H), 
4.78 (t, 1H),  5.08 (s, 2H), 6.85 (d, J  = 8.4 Hz, 1H), 7.00 (s, 
1H), 7.04 (d, 1H), 7.31 (d, J  = 6.8 Hz, 1H), 7.37 (t, J  = 7.2 
Hz, 2H), 7.50 (s, 1H,  -NH), 7.61 (d, J  = 7.6 Hz, 2H), 8.20 
(s, 1H); 13C NMR 101.3 MHz, CDCl3) δ ppm 10.7, 13.2, 
41.3, 55.8, 59.7, 64.1, 72.1, 109.3, 114.3, 118.5, 125.8(2), 
126.2, 126.6, 128.4(2), 128.6, 132.7, 135.7, 147.6, 148.8, 
149.9, 151.2, 154.2, 164.2; ESIMS  m/z 418.3[M + H]+ . 
2-(5-(4-((4-Methoxy-3,5-dimethyl pyridin-2-yl)methoxy)-3-
methoxy phenyl) -4,5-dihydro-1H-pyrazol-3-yl)phenol (8) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.20 (s, 3H), 2.24 
(s, 3H), 2.98 (dd, J  = 12.8 & 11.2 Hz, 1H), 3.54 (dd, J  = 
10.4 & 10.4 Hz, 1H), 3.72 (s, 6H), 4.77(t, J  = 10.0 Hz, 1H), 
5.07(s, 2H), 6.85 - 6.89 (m, 3H), 7.02 (s, 1H), 7.05 (d, J  = 
8.0 Hz, 1H), 7.20 (t, J  = 8.0 Hz, 1H), 7.27 (d, J  = 8.0 Hz, 
1H) , 7.75 (s, 1H,  -NH), 8.19 (s, 1H), 11.15 (s, 1H, -OH); 
13C NMR (101.3 MHz, CDCl3) δ ppm 10.7, 13.21, 41.4, 
55.8, 59.7, 62.5, 71.9, 109.6, 114.3, 116.3(2), 118.5, 118.9, 
126.2, 126.6, 127.4, 130.1, 134.8, 147.7, 148.7, 149.9, 154.0, 
154.1, 157.5, 164.1; ESIMS  m/z 434.3[M + H]+ . 
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2-(5-(4-((4-Methoxy-3,5-dimethylpyridin-2-yl)methoxy)-3-
methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-4-methylphenol 
(9) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.20 (s, 3H), 2.24 
(s, 3H), 2.36 (s, 3H), 2.99 (dd, J  = 12.8 & 11.2 Hz, 1H), 
3.54 (dd, J  = 10.4 & 10.4 Hz, 1H), 3.72 (s, 6H), 4.77 (t, 1H), 
5.08 (s, 2H), 6.85-6.89 (m, 2H), 7.02 (s, 1H), 7.05 (d, J  = 
8.0 Hz, 1H), 7.20 (t, J  = 7.6 Hz, 1H), 7.27 (d, J  = 8.0 Hz, 
1H), 7.75 (s, 1H, -NH), 8.19 (s, 1H), 11.15 (s, 1H, -OH); 13C 
NMR (101.3 MHz, CDCl3) δ ppm 10.74, 13.21, 31.12, 
41.49, 55.81, 59.72, 62.5, 71.9, 109.6, 114.3, 116.3, 118.5, 
118.9, 126.2, 126.6, 127.4, 130.1(2), 134.8, 147.7, 148.7, 
149.9, 154.0, 154.1, 157.5, 164.1; ESIMS  m/z 448.4 [M + 
H]+. 
2-((4-(3-(4-Fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-
methoxyphenoxy)methyl)-3,4-dimethoxypyridine (10) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.22 (3H, s),  2.25 
(3H, s), 2.84 (1H, dd, J = 10.8 & 10.8 Hz), 3.37 (1H, dd, J  
= 10.8 &10.8 Hz), 3.73 (6H, s), 4.78 (1H, t, J  = 10.4 Hz), 
5.08 (2H, s), 6.85 (1H, d, J = 8.4 Hz), 7.00 (1H, s), 7.05 (1H, 
d, J  = 8.4 Hz), 7.22 (1H, t,  J  = 8.0 Hz), 7.49 (1H, s), 7.65 
(1H, t, J  = 6.8 Hz), 8.20 (1H, s); 13C NMR (101.3 MHz) in 
CDCl3) δ ppm 10.7, 13.1, 41.3, 55.7, 59.6, 64.1, 71.9, 109.5, 
114.2, 115.2, 115.4, 118.4, 126.1, 126.5, (127.4,127.5), 
(129.03, 129.06), 135.5,147.5, 148.7, 149.8, 150.1, 154.1, 
161.5 (F-C), 164.0 (F-C), 164.1; ESIMS  m/z 436.3 [M + 
H]+. 
6-(5-(4-((4-Methoxy-3,5-dimethylpyridin-2-yl)methoxy)-3-
methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-
benzo[b][1,4]oxazin-3(4H)-one (11) 
1H NMR (400 MHz, DMSO-d6) δ ppm 2.22 (s, 3H), 2.25 
(s, 3H), 2.78 (dd, J  = 11.2 & 11.2 Hz, 1H), 3.34 (dd, J  = 
12.8 Hz & 12.8 Hz, 1H), 3.73 (s, 3H), 3.74 (s, 3H), 4.59 (s, 
2H), 4.75 (t, J  = 10.8 Hz, 1H), 5.08 (s, 2H), 6.85 (d, J  = 8.0 
Hz, 1H), 6.93 (d, J  = 8.4 Hz, 1H), 7.0 (s, 1H), 7.05 (d, J  = 
8.0 Hz, 1H), 7.09 (d, J  = 8.8 Hz, 1H), 7.25 (s, 1H), 7.40 (s, 
1H,  -NH), 8.2 (s, 1H),   10.79 (bs, 1H); 13C NMR (101.3 
MHz, CDCl3) δ ppm 10.7, 13.2, 41.5, 55.7,59.7, 63.8, 67.0, 
71.7, 109.7, 113.0, 114.2, 116.4, 118.5, 122.0, 126.2, 126.5, 
126.6, 127.4, 135.5, 144.1, 147.5, 148.6, 149.8, 150.6, 154.0, 
164.2, 165.6; ESIMS  m/z 490.3 [M + H]+ . 
3-(4-(4-(4-(4,5-Dihydro-3-phenyl-1H-pyrazol-5-yl)-2-methoxy-
phenoxy)butyl)piperazin-1-yl)benzo[d]isothiazole (12) 
1H NMR (400 MHz, DMSO-d6) δ ppm 1.61 (m, 2H), 1.75 
(m, 2H),  2.45 (t, 2H), 2.59 (bpeak, 4H), 2.98 (dd, J  = 11.2 
Hz & 11.2 Hz, 1H), 3.63 (dd, J  = 10.4 Hz & 11.2 Hz, 1H), 
3.43 (bpeak, 4H),  3.75 (s, 3H), 3.97 (t, 2H), 4.78 (t, 1H), 
6.86 (d, J  = 2.4Hz, 1H), 6.93 (d, J  = 8.4 Hz, 1H),  7.01 (t, J  
= 2.4 Hz, 1H), 7.31 (t, J  = 7.2 Hz, 1H),  7.43 (t, J  = 6.8 Hz, 
2H), 7.52 (d, J  = 3.6 Hz, 1H, -NH), 7.56 (t, J  = 5.4 Hz, 1H),  
7.62 (d, J  = 7.2 Hz, 2H), 8.05 (d, J  = 8 Hz, 2H); ESIMS  
m/z 542.4 [M + H]+. 
2-(5-(4-(4-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)butoxy)-3-
methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)phenol (13) 
1H-NMR (400 MHz, CDCl3) δ ppm 1.61 (m, 2H), 1.75 (m, 
2H) H2, 2.42 (t, 2H), 2.59 (m, 4H), 2.98 (dd, J  = 11.6 & 
11.2 Hz, 1H), 3.43 (bpeak, 4H), 3.56 (dd, J  = 10.4 & 10.4 
Hz, 1H), 3.76 (s, 3H), 3.97 (t, 2H), 4.78 (t, 1H), 6.86-6.95 
(m, 4H ), 7.03 (d, J  = 2.4 Hz, 1H), 7.23 (t, J  = 8.0 Hz, 1H), 
7.29 (dd, J  = 1.2 & 8.4 Hz, 1H), 7.43 (t, J  = 8.0 Hz, 1H), 
7.56 (t, J  = 8.0 Hz, 1H), 7.78 (d, J  =  8.0 Hz, 1H), 8.04 (d, 
J = 8.4 Hz, 2H), 11.18 (s, 1H), 8.17 (d, J = 8.0 Hz , 2H); 13C 
NMR (101.3 MHz, CDCl3)  δ ppm 23.2, 27, 41.6, 49.9(2),  
52.9(2), 55.9, 58.1, 62.6, 68.7, 109.7,  113.0, 116.4, 118.6, 
118.9, 120.4, 127.37, 127.60, 123.7, 123.8, 127.4, 127.4, 
127.9, 130.2, 134.3, 148.1, 149.6, 152.6, 154.2, 157.6, 
163.8; FT-IR (KBr) cm-1 758, 838, 1137, 1236, 1253, 1375, 
1484, 1592 & 1514; ESIMS  m/z 558.4 [M + H]+ . 
3-(4-(4-(4-(3-(4-Fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl)-2-
methoxyphenoxy)butyl)piperazin-1-yl) benzo[d]isothiazole (14) 
1H NMR (400 MHz, DMSO-d6) δ ppm 1.74 (m, 2H), 1.90 
(m, 2H), 2.51 (t, 2H), 2.66 (m, 4H), 3.00 (dd, J  = 9.2 Hz & 
9.2 Hz, 1H ), 3.42 (dd, J  = 10.8 Hz & 10.8 Hz, 1H ), 3.56 (t, 
4H), 3.85 (s, 3H), 4.06 (t, 1H), 4.88 (t, 2H), 6.87 (d, J  = 8.0 
Hz, 1H ), 6.93 (d, J  = 8.4 Hz, 1H), 6.99 (d, J  = 2.4 Hz, 1H), 
7.21 (t, 1H ), 7.43 (t, 1H), 7.51 (d, J  = 3.6 Hz,  2H), 7.65 
(dd, J = 5.2 Hz & 5.6 HZ, 2H), 8.05 (d, J  = 8.4 Hz, 2H); 13C 
NMR (101.3 MHz, CDCl3) δ ppm 23.2, 27.0, 41.5, 49.95(2), 
52.9(2), 55.9, 58.1, 64.2, 68.7, 109.7, 112.7, 115.3, 115.5, 
118.5, 120.4, 123.8(2), 127.4, 127.6, 127.7, 127.9, 129.1, 
135.0, 148.0, 149.6, 150.4, 152.6, 162.0 (F-C), 163.8, 
164.0(F-C); ESIMS m/z 560.4 [M + H]+. 
6-((R)-5-(4-(4-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)but-
oxy)-3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-2H-
benzo[b][1,4]oxazin-3(4H)-one (15) 
1H NMR (400 MHz, DMSO-d6) δ ppm 1.61 (m, 2H), 1.74 
(m, 2H), 2.42 (t, 2H), 2.59 (bpeak, 4H), 2.77 (dd, J  = 10.8 
Hz & 10.8 Hz, 1H), 3.31 (dd, J  = 10.4 & 10.2 Hz, 1H), 3.33 
(bpeak, 4H), 3.75 (t, 3H), 3.96 (t, 2H), 4.59 (s, 2H), 4.69 (t, 
1H), 6.84 (d, J  = 8.4 Hz, 2H), 6.926 (d, J  = 7.6 Hz, 2H), 
6.98 (d, J  = 1.2 Hz, 1H), 7.08 (d, J  = 8.0 Hz, 1H), 7.263 (d, 
J  = 1.6 Hz, 1H), 7.41-7.45 (m, 2H), 7.55 (t, 1H), 8.05 (d, J  
= 8.0 Hz, 2H), 13C NMR (101.3 MHz, CDCl3) δ ppm 23.2, 
27.0, 41.6, 49.9(2), 52.9(2), 55.9, 58.1, 63.9, 67.1, 68.7, 
109.8, 112.9, 116.5, 118.5, 120.4(2), 122.2, 123.7, 123.8, 
126.5, 127.4, 127.5, 127.9, 134.9, 144.2, 147.9, 149.5, 150.7, 
152.6, 163.8, 165.6;  ESIMS m/z 613.4 [M + H]+. 
3-(4-(4-(4-(3-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-6-yl)-
4,5-dihydro-1H-pyrazol-5-yl)-2-methoxyphenoxy)butyl)-
piperazine-1-yl)benzo[d]isothiazole (16) 
1H NMR (400 MHz, DMSO-d6) δ ppm 1.51 (d, 6H), 1.62 
(m, 2H), 1.74 (m, 2H), 2.42 (m, 2H), 2.59 (bpeak, 4H), 2.95 
(dd, J  = 11.2 Hz & 10.8 Hz, 1H), 3.43 (bpeak, 4H), 3.50 (dd, 
J  = 10.4 & 10.4 Hz, 1H), 3.76 (s, 3H), 3.97 (d, 2H), 4.78 (t, 
1H), 4.81 (m, 1H), 6.89 (m, 3H), 7.03 (s, 1H), 7.24-7.32 (m, 
3H), 7.43 (t, 1H), 7.56 (t, 1H), 7.62 (t, 2H), 7.71 (dd, J  =  
5.6 Hz & 5.6 Hz, 2H), 7.85 (s, 1H), 7.95 (s, 1H), 8.05 (d, J  
=  7.2 Hz, 2H); 13C NMR (101.3 MHz, CDCl3)  δ ppm  22.7, 
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23.2, 27.1, 42.0, 47.3, 49.9(2), 52.9(2), 55.9, 58.2, 63.9, 68.8, 
109.7, 110.0, 112.9, 115.4, 115.6, 116.6, 117.9, 118.1, 118.6, 
120.1, 120.4, 121.8, 123.7, 123.8, 125.1, 126.0, 127.4, 
127.9(2), 128.7, 128.8, 131.4, 135.6, 136.3, 147.9, 149.6, 
152.6, 152.9, 163.8; ESIMS m/z 717.6 [M + H]+ . 
3-(4-(4-(4-(4,5-Dihydro-1,3-diphenyl-1H-pyrazol-5-yl)-2-meth-
oxyphenoxy)butyl)piperazin-1-yl)benzo[d]isothiazole (17) 
1H NMR (400 MHz, CDCl3) δ ppm 1.72 (m, 2H), 1.88 (m, 
2H), 2.47 (t, d, J  = 7.2 Hz, 2H), 2.67 (bpeak, 4H), 3.14 (dd, 
J  = 7.6 Hz & 7.6 Hz, 1H), 3.56 (bpeak, 4H), 3.77-3.84 (m, 
4H), 4.04 (t, J  = 6.8 Hz, 2H), 5.18 (dd, J  = 8.0 Hz & 8.0 Hz, 
1H), 6.78 (t, J  = 7.6 Hz, 1H), 6.82-6.87 (m, 3H), 7.09 (d, J  
= 8.0 Hz  2H), 7.17 (t, J = 8.0 Hz, 2H), 7.32-7.40 (m, 4H), 
7.46 (t, J  =  7.6 Hz, 1H), 7.73 (d, J  = 7.2 Hz, 2H), 7.80 (d, 
J = 8.0 Hz, 1H), 7.90 (d, J  = 8.0 Hz, 1H); 13C NMR 
( CDCl3) δ ppm 23.3, 27.1, 43.6, 50.0(2), 52.9(2), 55.9, 58.2, 
64.6, 68.7, 109.0, 113.1, 113.4(2), 118.0, 119.1, 120.5, 
123.7, 123.8, 125.6(2), 127.4, 127.9, 128.4(2), 128.7(2), 
132.7, 135.2, 145.1, 146.8, 147.7, 149.9, 152.6, 163.8; 
ESIMS m/z 618.5 [M + H]+ . 
3-(4-(4-(4-(3-(4-Fluorophenyl)-4,5-dihydro-1-phenyl-1H-pyra-
zol-5-yl)-2-methoxyphenoxy) butyl)piperazin-1-yl)benzo[d]iso-
thiazole (18) 
1H NMR (400 MHz, DMSO-d6) δ ppm 1.73 (m, 2H), 1.89 
(m, 2H), 2.50 (t, 2H), 2.69 (bpeak, 4H), 3.11 (dd, J  = 7.6 Hz 
& 7.2 Hz, 1H), 3.56 (bpeak, 4H),  3.75-3.88 (m, 4H), 4.04 (t, 
J  = 7.2 Hz, 2H), 5.19 (dd, J  = 8.0 Hz, 8.0 Hz, 1H), 6.73 (t, 
J  = 7.6 Hz, 1H), 6.84 (d, J  = 8.8 Hz, 2H), 7.08 (d, J  = 4.4 
Hz, 2H),  7.32-7.36 (m, 2H), 7.42-7.47 (m, 2H),  7.55-7.58 
(m, 2H), 7.80 (d, J  = 8.0 Hz, 1H), 7.18 (t, J  = 7.6 Hz, 2H), 
7.36 (t, J  = 7.2 Hz, 2H), 7.47 (t, J  = 7.6 Hz, 1H), 7.71 (t, J  
= 7.6 Hz, 2H), 7.81(d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.0 Hz, 
1H); ESIMS  m/z 636.5 [M + H]+ . 
3-(4-(4-(4-(3-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-6-yl)-
4,5-dihydro-1-phenyl-1H-pyrazol-5-yl)-2-methoxyphenoxy)-
butyl)piperazin-1-yl)benzo[d]isothiazole (19) 
1H NMR (400 MHz, DMSO-d6) δ ppm 1.58 (m, 6H), 1.72 
(m, 2H),  1.89 (m, 2H), 2.49 (t, 2H), 2.67 (bpeak, 4H), 3.23 
(dd, J  = 10.8 Hz & 11.2 Hz, 1H), 3.56 (bpeak, 4H),  3.79 (s, 
3H), 3.90 (dd, J  = 10.2 Hz & 10.8 Hz, 1H), 4.03 (t, 2H), 
4.73 (m, 1H), 5.15 (dd, J  = 9.6 Hz & 9.6 Hz, 1H), 6.74-6.90 
(m, 5H), 7.09-7.20 (m, 5H), 7.32-7.36 (m, 2H), 7.42-7.47 (m, 
2H),  7.55-7.58 (m, 2H), 7.80 (d, J  = 8.0 Hz, 1H), 7.91 (dd, 
J  = 8.4 Hz & 5.6 Hz, 2H), 7.94 (s, 1H); 13C NMR (101.3 
MHz, CDCl3) δ ppm 22.8(2), 27.1, 44.2, 47.3, 50.0(2), 
52.9(2), 55.98, 58.2, 64.6, 68.7, 109.1, 110.1, 113.1, 
113.3(2), 115.5, 115.7, 116.7, 117.6, 118.0, 118.7, 120.0, 
120.5(2), 121.8, 123.8, 123.8, 125.0, 126.0, 127.4(2), 128.0, 
128.7, 128.8, 131.4, 131.4, 135.7, 136.3, 145.6, 147.7, 148.4, 
150.0, 152.7, 160.1, 162.6, 163.9; ESIMS  m/z 793.7 
[M+H]+. 
 
RESULT AND DISCUSSIONS 
In this communication, two new series of pyrazoline 
containing substituted chloromethyl pyridine and alkoxy 
linkage side chain containing benzoisothiazole represented 
as in Schemes 1 and 2. The essentials of synthesized 
compounds were confirmed by their physical properties and 
spectroscopic techniques like 1H NMR, 13C NMR, Mass 
spectroscopy and FT-IR.  
Substituted chloromethylpyridines were treated with 
vanillin at room temperature in the presence of potassium 
carbonate and DMF used as a solvent to get aldehydes. 
These aldehydes were reacted further with different 
acetophenones, as shown in Table 1, in the presence of 30 % 
aq. KOH solution where ethanol used as a solvent in the 
reaction to form the respective chalcones. Pyrazolines were 
synthesized by refluxing chalcones with hydrazine hydrate 
in the presence of ethanol as the solvent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of pyrazoline compounds (1-11). 
Spectroscopic data confirmed the assigned structure for 1-
19, where its 1H NMR, 13C NMR and mass spectroscopy 
where disappearance of the C=C bond two trans proton 
coupling having J value ~16.0 Hz of chalcones and 
formation of three peaks displayed in pyrazoline (δ ~2.8, 3.4 
and a triplet at ~4.7 ppm (D2O-exchangeable, 1H, NH)). 
13C-NMR shows signals corresponding to respective types 
of carbon in different chemical shifts of pyrazoline 
compounds details of the chemical shift were captured in the 
characterization part.   
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Scheme 2. Synthesis of pyrazoline and phenyl pyrazoline compounds (12-19): Reaction conditions a) K2CO3/DMF/1,4-dibromobutane, 
dichloromethane and water. b) K2CO3/DMF/3-(piperazin-1-yl)benzo[d]isothiazole, isopropyl alcohol. c) 30% aq. solution of KOH.  d) 
NH2NH2/ethanol/  e) PhNHNH2, EtOH,  
 
Mass spectroscopy gives corresponding [M+1] molecular 
ion peak at their corresponding molecular weight, as shown 
in Table 1. The IR spectrum of compounds showed a broad 
band at ~3446 cm-1 recognized for -OH group and the 
characteristic N=N band was assigned at 1591 cm-1 two 
strong bands at ~1650 cm-1 and ~1607 cm-1 referring to 
carbonyl and carbon-carbon double bond disappearance 
confirmed the formation of pyrazolines compounds. 
The synthesized compounds were assigned on the basis of 
1H NMR, 13C NMR, mass and IR spectral analytical studies 
to confirm the proposed structures. Physical constant data 
were tabulated in Table 1.  
Molecular docking  
To study binding conformations of the synthesized 
compounds, the Autodock Vina program was used for 
docking pyrazoline derivatives into the active sites of 
methionyl-tRNA synthetase. The AutoDock Tools 1.5.4 
(ADT) was used to prepare the input files for docking.18 The 
crystal structure of Thermus thermophilus methionyl-tRNA 
synthetase reveals two RNA-binding modules. All water 
molecules and ions were removed from the protein 
crystallographic structures; polar hydrogens were added and 
partial atomic charges were assigned by Kollman united 
charges method.19-21  
Sidechains of lysine, arginine, and histidine residues were 
protonated while the carboxylic groups of glutamic and 
aspartic acid were deprotonated. For each ligand, nonpolar 
hydrogens were merged, Gasteiger charges were assigned 
and rotatable bonds were set up. The structures were then 
saved in the corresponding pdbqt file required for the 
Autodock. 
 
Antioxidant activity 
Antioxidant potential of the synthesized compounds was 
measured in terms of DPPH, OH and superoxide radical 
(SOR) scavenging activity carried out using reported 
methods.22 following the procedure as discussed in our 
previous publications.16 The results of antioxidant activity 
are summarized in Table 2. The detailed procedure for the 
antioxidant activity is provided in the supplementary 
material.  
Antimicrobial screening 
To confirm the inhibitory activity, the hit compounds were 
re-tested against the strains in a dose-response assay to 
determine the minimum inhibitory concentration (MIC) of 
the compounds.  Samples were prepared in DMSO and 
water to a final testing concentration of 32 μg mL-1 or 20 
μM in 384-well, non-binding surface plate (NBS) for each 
bacterial/fungal strain, in duplicate (n=2), and keeping the 
final DMSO concentration to a maximum of 1 % DMSO. 
All the sample-preparation was done using liquid handling 
robots. All bacteria were cultured in cation-adjusted Mueller 
Hinton broth (CAMHB) at 37 °C overnight. A sample of 
each culture was then diluted 40-fold in fresh broth and 
incubated at 37 °C for 1.5-3 h. The resultant mid-log phase 
cultures were diluted (CFU mL-1 measured by OD600), 
added to each well of the compound containing plates giving 
a cell density of 5×105 CFU mL-1 and a total volume of 50 
μL. All the plates were covered and incubated at 37 °C for 
18 h without shaking. 
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Table 1. Physical constant of the synthesized compounds. 
Code Structure of compounds Molecular 
formula 
Molecular 
wt. 
M. P., 
oC 
Yield, 
% 
1 N
O
O
H3C
O
CH3
O
CH3 HN N  
C24H25N3O4 419.47 171 92 
2 
N
O
O
H3C
O
CH3
O
CH3
HO
HN N  
C24H25N3O5 435.47 176 87 
3 N
O
O
H3C
O
CH3
O
CH3
HO
HN N
CH3
 
C25H27N3O5 449.5 175 83 
4 N
O
O
H3C
O
CH3
O
CH3
MeO
HN N  
C25H27N3O5 449.5 173 85 
5 N
O
O
H3C
O
CH3
O
CH3 HN N
F
 
C24H24FN3O4 437.46 169 88 
6 N
O
O
H3C
O
CH3
O
CH3
N
H
O
O
NHN  
C26H26N4O6 490.51 207 93 
7 N O
O
H3C
CH3
O
H3C
H3C
HN N  
C25H27N3O3 417.5 161 70 
8 N O
O
H3C
CH3
O
H3C
H3C
N
HO
HN  
C25H27N3O4 433.5 163 68 
9 N O
O
H3C
CH3
O
H3C
H3C
HO
CH3
HN N  
C26H29N3O4 447.53 165 69 
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N
O
CH3
H3C
O
O
F
HN N
H3C
H3C
 
C25H26FN3O3 435.49 166 70 
11 N O
O
H3C
CH3
O
H3C
H3C
N
H
O
O
HN N  
C27H28N4O5 488.54 225 72 
12 O
O
N
N
S
N CH3
H
N N
 
C31H35N5O2S 541.71 163 69.8 
13 O
O
N
N
S
N
HO
CH3
N
H
N
 
C31H35N5O3S 557.71 171 78 
14 O
O
N
N
S N
CH3 NHN
F
 
C31H34FN5O2S 559.7 160 79 
15 O
O
N
N
S
N
N
CH3
H
N
O
H
N O
 
C33H36N6O4S 612.74 171 78 
16 
O
O
N
N
S N
CH3
N
H3C CH3
F
HN N
 
C42H45FN6O2S 716.91 172 80 
17 
SN
NN
OO
CH3
N
N
 
C37H39N5O2S 617.8 168 71 
18 SN
NN
OO
CH3
N
N
F
 
C37H38FN5O2S 635.79 164 69 
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O
O
CH3
N
H3C CH3
F
NN
N
N
N S
 
C48H49FN6O2S 793.01 174 70 
 
 
Table 2. Radical scavenging profile of the synthesized compounds 
Compound  % Radical scavenging activity 
DPPH OH SOR 
1 NR 44.76 ± 1.03 32.74 ± 1.27 
2 40.76 ± 1.76 26.01 ± 1.09 60.52 ± 1.03 
3 20.76 ± 1.63 11.59 ± 1.36 32.41 ± 0.89 
4 23.62 ± 1.61 11.99 ± 0.72 41.36 ± 0.56 
5 78.52 ± 1.51 07.82 ± 0.64 52.16 ± 2.14 
6 37.09 ± 1.49 31.95 ± 0.76 53.14 ± 1.29 
7 39.16 ± 0.13 27.03 ± 0.14 32.63 ± 1.34 
8 56.93 ± 1.93 12.04 ± 1.20 21.52 ± 1.87 
9 41.15 ± 2.14 12.70 ± 1.91 43.87 ± 1.64 
10 52.71 ± 1.02 12.48 ± 1.85 36.46 ± 1.35 
11 20.28 ± 0.21 34.61 ± 1.43 35.82 ± 0.87 
12 33.11 ± 0.52 10.49 ± 1.84 37.42 ± 1.49 
13 47.53 ± 0.63 31.95 ± 0.12 53.45 ± 1.26 
14 64.02 ± 0.84 15.43 ± 0.46 45.61 ± 1.47 
15 59.88 ± 2.14 17.31 ± 1.74 37.46 ± 1.67 
16 37.81 ± 1.84 21.22 ± 1.61 44.21 ± 1.34 
17 68.88 ± 0.83 07.82 ± 1.76 55.41 ± 0.57 
18 78.88 ± 0.73 31.95 ± 0.73 65.43 ± 0.39 
19 75.02 ± 2.59 31.98 ± 2.46 37.63 ± 0.16 
*AA 91.25 ± 1.91 89.11 ± 1.67 79.86 ± 1.24 
    
*AA: ascorbic acid. Results represented here are the mean of 
n=3±SD. NR: No reaction under the experimental conditions. 
Fungi strains were cultured for 3 days on yeast extract-
peptone dextrose (YPD) agar at 30 °C. A yeast suspension 
of 1 x 106 to 5 x 106 CFU mL-1 (as determined by OD530) 
was prepared from five colonies. The suspension was 
subsequently diluted and added to each well of the 
compound containing plates giving a final cell density of 
fungi suspension of 2.5 ×103 CFU mL-1 and a total volume 
of 50 μL. All plates were covered and incubated at 35 °C for 
24 h without shaking. 
Colistin and Vancomycin were used as positive bacterial 
inhibitor standard for gram-negative and gram-positive 
bacteria, respectively. Fluconazole was used as a positive 
fungal inhibitor standard for C. Albicans and C. neoformans. 
The antibiotics were provided in 4 concentrations, with 2 
above and 2 below its MIC value, and plated into the first 8 
wells of column 23 of the 384-well NBS plates. The quality 
control (QC) of the assays was determined by the 
antimicrobial controls and the Z'-factor (using positive and 
negative controls). Each plate was deemed to fulfill the 
quality criteria (pass QC) if the Z'-factor was above 0.4, and 
the antimicrobial standards showed the full range of activity, 
with full growth inhibition at their highest concentration, 
and no growth inhibition at their lowest concentration.  
The inhibition of bacterial growth was determined by 
measuring absorbance at 600 nm (OD600) using a Tecan 
M1000 Pro monochromator plate reader. The percentage of 
growth inhibition was calculated for each well using the 
negative control (media only) and positive control (bacteria 
without inhibitors) on the same plate as references. The 
significance of the inhibition values was determined by 
modifying Z-scores, calculated using the median of the 
samples (no controls) on the same plate. Samples with 
inhibition values above 80 % and Z-score above 2.5 for 
either replicate (n=2 on different plates) were classed as 
actives, whereas samples with inhibition values between 50 
– 80 % and Z-score below 2.5 for either replicate (n=2 on 
different plates) were classed as partially active. 
Table 3. Material assays for antimicrobial activity 
Material Code Brand Catalogue 
No. 
Compound 
preparation Plate PP Corning 3364 
Assay plates NBS 384w Corning 3640 
Growth media-
bacteria CAMHB 
Bacto 
Laboratories 212322 
Culture agar-fungi YPD Becton Dickinson 242720 
Growth media-
fungi YNB 
Becton 
Dickinson 233520 
Resazurin  Sigma-Aldrich R7017 
    
Percentage growth inhibition of individual samples was 
calculated based on negative controls (media only) and 
positive controls (bacterial media without inhibitors). The 
percentage of growth inhibition was calculated for each well 
using the negative control (media only) and positive control 
(without inhibitors) on the same plate. The growth rates for 
all bacteria and fungi have a variation of -/+ 10 %, which 
lies is within the expected normal distribution of microbial 
growth. 
 
Molecular docking  
The synthesized compounds were docked against the 
active site of Thermus thermophilus methionyl-tRNA 
synthetase using Autodock vina docking tool whose results 
were expressed in terms of docking scores (Table 8). 
Analysis of docking interaction reveals that the pyrazoles 
bearing benzoisothiazole ring (12, 13 and 15) were the most 
active compounds against methionyl-tRNA synthetase. 
Results of observed antimicrobial activities are in good 
agreement for these tilted compounds in terms of higher 
negative values of Z-scores. 
The benzisothiazole linked pyrazolines 12, 13 and 15 bind 
efficiently into the active site residues like TYR13, GLU54, 
ARG132, ASP50, ASP260, GLY21, HIS22, LEU290, 
ILE261, VAL226, and LYS297.  
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Table 4. Standards for antimicrobial activity 
Sample Sample ID Full MW Stcok conc. 
µg mL-1 
Solvent Source 
Colistin Sulfate MCC_000094:02 1400.63 10.0 DMSO Sigma; C4461 
Vancomycin HCL MCC_000095:02 1485.71 10.0 DMSO Sigma; 861987 
Fluconazole MCC_008383:01 306.27 2.56 DMSO Sigma; F8929 
 
Table 5. Bacterial and fungal species used along with abbreviations 
ID Batch Microbe Strain Description 
GN_001 02 Escherichia coli ATCC 25922 FDA control strain 
GN_003 02 Klebsiella pneumoniae ATCC 700603 MDR 
GN_034 02 Acinetobacter baumannii ATCC 19606 Type strain 
GN_042 02 Pseudomonas aeruginosa ATCC 27853 Quality control strain 
GP_020 02 Staphylococcus aureus ATCC 43300 MRSA 
FG_001 01 Candida albicans ATCC 90028 CLSI reference 
FG_002 01 Cryptococcus neoformans ATCC 208821 Type strain 
All antibiotic controls displayed inhibitory values within the expected range. 
Table 6. Brief results of antimicrobial activity 
Strain ID Microba Antibiotic Pass / Fail 
GN_001:02 E. coli Colistin Pass 
GN_003:02 K. pneumoniae Colistin Pass 
GN_034:02 A. baumannii Colistin Pass 
GN_042:02 P. aeruginosa Colistin Pass 
GP_020:02 S. aureus (MRSA) Vancomycin Pass 
FG_001:01 C. albicans Fluconazole Pass 
FG_002:01 C. neoformans (H99) Fluconazole Pass 
 
Table 7. Different bacteria, fungi and abbreviations used for antimicrobial activity 
Abbreviation Name Description Strain Organism Type 
Sa Staphylococcus aureus MRSA ATCC 43300 Bacteria G+ve 
Ec Escherichia coli FDA control ATCC 25922 Bacteria G-ve 
Kp Klebsiella pneumoniae MDR ATCC 700603 Bacteria G-ve 
Ab Acinetobacter baumannii Type strain ATCC 19606 Bacteria G-ve 
Pa Pseudomonas aeruginosa Type strain ATCC 27853 Bacteria G-ve 
Ca Candida albicans CLSI reference ATCC 90028 Fungi Yeast 
Cn Cryptococcus neoformans var. grubii Type strain H99; ATCC 208821 Fungi Yeast 
  
 
The 2H-1,4-benzoxazin-3(4H)-one derivatives 15 (-
8.5243) interacts with the polar and charged amino acid 
residues THR55 and GLU54 with a carbonyl oxygen atom 
and an oxygen atom of oxazine at the distance of 1.90, 1.93 
and 1.93 Å to form conventional hydrogen bond interactions. 
The charged amino acid ASP50 and hydrophobic amino 
acid TYR13 form conventional hydrogen bond interactions 
with pyrazole nitrogen and methoxyl oxygen atom with a 
distance of 1.87 and 1.90 Å, respectively. The polar amino 
acid HIS22 and ASP260 amino acid interact with a 
methoxyl hydrogen atom and the hydrogen atom of the 
piperazine ring to form a C-H bond and conventional 
hydrogen bond interactions.  
The aliphatic amino acids VAL226, ILE261, GLY288, 
LEU290, and charged amino acid LYS297 interact with π 
electron cloud to form π-donor hydrogen and π-alkyl 
interactions (Figure 1).  
The benzoisothiazole derivative 12 (-7.9567) interacts 
with the polar and charged amino acid of the active site. The 
charged amino acid ASP260 interacts with hydrogens of the 
piperazine ring to form conventional hydrogen bond 
interactions and C-H bond at a distance of 1.96, 2.53, 2.59 
and 2.54 Å, respectively.  
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Table 8. In vitro activity and molecular docking of synthesized compounds 
Compound 
code 
Z-Score Free binding 
energy, kcal mol-1 Sa Ec Kp Pa Ab Ca Cn 
1 1.76 1.29 0.73 0.6 1.12 -4.54 1.95 -6.4069 
2 0.96 -0.13 -1.09 1.33 -0.42 -2.63 1.52 -5.6208 
3 1.31 -0.52 0.96 -1.56 0.14 0.05 -0.21 -6.9635 
4 1.13 1.24 0.97 -1.04 0.21 0.49 0.05 -6.0319 
5 0.29 -0.2 0.73 -0.6 0.34 -2.25 -0.13 -7.2436 
6 0.13 0 0.7 -1.23 0.08 0.1 2.19 -6.584 
7 0.99 -1.17 83 -0.62 0.32 0.55 -0.12 -4.5155 
8 0.95 1 1.39 0.2 1.24 0.63 0.74 -6.3774 
9 1.4 -1.66 0.7 -1.53 0.54 -0.83 -0.13 -5.5377 
10 -0.11 0.04 -0.57 -1.35 -0.86 -0.89 0.22 -5.2221 
11 -0.74 -1.24 -0.72 -0.8 -1.16 -0.48 2.11 -6.1736 
12 0.72 1.38 0.26 0.65 1 0.47 -2.78 -7.9567 
13 0.49 -0.49 0.52 -1.46 -0.19 -0.11 -2.77 -7.6732 
14 0.24 0.83 0.44 -1.64 0.2 0.55 -0.81 -6.6984 
15 0.39 -0.08 0.28 0.76 -0.04 0.67 -2.91 -8.5248 
16 1.34 1.13 1.76 1.19 -1.62 -1.11 -0.41 -6.9736 
17 3.31 3.77 3.9 0.9 2.53 -5.85 2.49 -6.351 
18 0.42 0.52 0.78 -0.43 0.24 0.12 1.17 -5.5277 
19 2.38 1.94 3.41 -0.23 3.39 -0.2 1.91 -5.112  
 
 
 
 
 
 
 
 
 
 
Figure 2. Binding pose and molecular interactions of 15 in the active site of methionyl-tRNA synthetase. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Binding pose and molecular interactions of 12 in the active site of methionyl-tRNA synthetase. 
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The polar amino acid THR55 and hydrophobic amino acid 
TYR13 interacts with pyrazole nitrogen atoms and phenoxy 
oxygen atom to form conventional hydrogen bond 
interaction with a distance of 2.00 and 2.52 Å respectively. 
The π-electron clouds of benzoisothiazole and phenoxy 
rings create π-sulfur, π-π stacked and π-alkyl interactions 
with various distances (Figure 2).        
CONCLUSION  
In summary, the present article reports a novel series of 
pyrazolines from chalcones and hydrazine hydrate or 
phenylhydrazine in the presence of ethanol as the alcoholic 
solvent. All structures of the newly synthesized molecules 
were characterized by spectroscopic data - 1H NMR, 13C 
NMR, Mass, and IR. Further, these newly synthesized 
compounds were evaluated for antioxidant and antimicrobial 
activity. Compounds 5, 18 and 19 were found to be 
potentially active antioxidants in terms of the DPPH radical 
scavenging assay, whereas 2 and 18 compounds showed 
better activity by superoxide radical (SOR) scavenging 
assay method in but less as compared with the standard 
ascorbic acid.  Compounds 12, 13 and 15 were partially 
active against Cryptococcus neoformans var. grubii fungi.  
The molecular docking study and in-vitro antibacterial and 
antifungal activity suggested that 12, 13 and 15 are the most 
active among all synthesized derivatives and will serve as 
excellent leads in the antimicrobial and antioxidant drug 
discovery process.   
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SILVER ATOMS ENCAPSULATED IN G4 PAMAM 
(POLYAMIDOAMINE) DENDRIMERS AS A MODEL FOR 
THEIR USE IN NANOMEDICINE FOR PHOTOTHERAPY 
Tamar G. Giorgadze [a]*, Irine G. Khutsishvili [a,b], Zaza G. Melikishvili [c] and 
Vasil G. Bregadze [a] 
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The main goals of the research are to study the drug delivery nanoparticle, G4 PAMAM (polyamidoamine) dendrimer, using spectroscopic 
and thermodynamic methods and, based on the unique properties of G4 PAMAM dendrimer, create new, stable nano-sized (∼5 nm) 
metalorganic nanocomplexes with silver atoms, which have a strong absorption in visible area and it can be used as a photo 
thermotherapeutic agent for the treatment of cancer cells.  
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INTRODUCTION 
In recent times, a major challenge in nanomedicine is to 
deliver medication in the local area of the disease or tumor. 
This can be achieved by using different nanosystems for 
drug delivery, which allows one to maximize clinical 
benefits and reduce the side effects of the drug.1-11 The 
organic nanoparticles must be non-toxicity. Further, the 
structure of the drug delivery complex should be maintained 
as much as possible before the delivery to the damaged 
tissue. In addition, after the complex is injected into the 
diseased cell, the drug must be released with the help of 
enzymes located in the cell.12-15 For the efficiency of drug 
delivery complex, the size of complex size is also important; 
due to clear reasons, it should be significantly smaller (at 
least by one order) than the size of the cell and at the same 
time, the amount of medicine located in the nanoparticles 
should be enough for cell treatment.16-20 
The main goals of nanomedicine is targeted delivery of 
therapeutic and diagnostic agents, their proper operation, 
and minimization of potential negative effects. Upon 
reaching the required places (perhaps using different 
mechanisms), therapeutic agents should selectively destroy 
or restore damaged cells, however, they should have little to 
no effect on the healthy tissue. Therefore, it should take into 
account the finest mechanisms to control the exact delivery 
of the agent. In oncology, nanomaterials are used for 
targeted delivery of therapeutic and diagnostic agents to 
tumor cells. Trapped in the bloodstream, specially treated 
nanomaterial accumulates in the tumor area, which is 
facilitated by the high permeability of tumor tissue (pore 
size of tumor tissue about 200 nm). It should be noted that 
the loading of tumor tissue with nanodrugs is much more 
effective than the loading of the same drugs with 
conventional diffusion.21,22 Some of them remain in the 
tumor tissue for quite a long time, which significantly 
increases the anti-neoplasmic effect of these substances. On 
the other hand, the wide surface of nanomaterial facilitates 
the better treatment of the targeted structures by the 
therapeutic agents.  
In the case of organic nanoparticles, a single hollow 
nanoparticle can contain hundreds of drug molecules, the 
extraction and function of which is strictly purposeful. 
Extraction of nanoagents in tumor tissue often occurs as a 
result of the degradation of nanocarriers, although there are 
other mechanisms of actions of anticancer nanodrugs. This 
requires strict control over the degradation of nanoparticles, 
the degree of degradation of nanoparticles depends on the 
composition of its polymer coating. The polymer coating of 
medical therapeutic and diagnostic nanocarriers are 
necessary for the felicitation of their movement in the body, 
"clearing the way" and protecting the therapeutic/diagnostic 
agents. 
Medical nanostructures, dendrimers, are synthetic 
branched polymers. Dendrimers have one starting atom, for 
example nitrogen, and as a result of a number of chemical 
reactions, it is linked to carbon and other elements. Each 
ending of the dendrimer contains reactive functional groups, 
so it easily attaches additional monomers, resulting in a 
dendrimer size increase. The dendrimer function is 
significantly related to its size, shape, and polarity.23,24 
Specifically, the hollow and branch structure of dendrimer is 
well-suited to the targeted delivery of the drug, and in some 
cases the same dendrimer can find the damaged cells and 
influence them.25-27 For example, in the tumor, one branch 
of the dendrimer may be treated with tumor detection 
molecules (for example folic acid, as many receptors for 
folic acid are on tumor cells) and the neighboring branch 
with anti-tumor drug. Dendrimer may also have an effect on 
specific receptors of specific sites.28-30 As a consequence of 
their unique structural topology and chemical versatility, 
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dendrimers have found (or are likely to find) applications 
that include catalysis,31-33 drug delivery,34,35 energy 
transfer,36-38 and molecular recognition.39,40  
In modern research, dendrimers are also used for synthesis 
of various metal nanoparticles. This means that the metal 
ions enter the existing hollow space in the structure of the 
dendrimer, and when the reductant (NaBH4) is added, they 
reduce to atoms and form a nanoparticle. In this case, the 
distribution of nanoparticle sizes is narrow.41  
Dendrimer types and their functional and synthesis 
conditions determine nanoparticle size, morphology and 
suspension stability.42 It should be noted that the reduction 
of some metal ions, for example silver, gold, platinum, 
palladium, is a complex process. At first, the copper ions are 
reduced and replaced with ions of other metals. With partial 
replacement, bimetallic nanoparticles can be formed.43 
Dendrimers encapsulated with metal nanoparticles are used 
as catalysts in some reactions: hydrogenations, 
hydroformylation, olefin metathesis, Heck reactions, Suzuki 
coupling, alkylation and oxidations. 
As one of the prospective delivery agent, we consider G4 
PAMAM (polyamidoamine) dendrimer (see Figure 1). Since 
the G4 PAMAM dendrimers satisfy all of the 
aforementioned qualities, they will satisfy the classification 
for drug delivery systems.9,10 In particular, dendrimers have 
advantages over other delivery agents. The unique and most 
important characteristics are chemical content, huge surface, 
spherical form, “pockets” full of water between the branches, 
which represent a kind of trap for the drug. In addition, they 
have certain molecular size and shape, they have a large 
number of functional groups on the surface and are 
characterized by high penetration in the cell.25,26,27,44 
 
 
 
 
 
 
 
 
 
Figure 1. Absorption spectrum and structure of G4(NH2)64 
PAMAM dendrimer. 
These characteristics of G4 PAMAM dendrimers gives us 
the opportunity to prepare new stable nanocomplexes (metal 
encapsulated G4 PAMAM dendrimers) with high absorption 
properties in visible and near infrared areas of the spectrum, 
which makes it possible to use them in nanomedicine.  
EXPERIMENTAL 
In our tests, we have used the Calf thymus DNA (40 % 
GC) obtained from Sigma. The concentration of nucleic 
acids was determined by UV absorption using molar 
extinction coefficients (ε=6600 cm-1 M-1 at λ=260 nm). The 
double helix structure of the polymers was proved by their 
hyperchromicity (>30 %) and their typical thermal 
denaturation transition (measured in 0.01 M NaNO3, pH ≅ 
6.0). The pH was checked by a pH-meter HANNA 
Instruments pH213. The G4(NH2)64 PAMAM dendrimer, 
with molecular sizes 4.5 nm, molecular weight 14215, was 
also purchased from Sigma (λ = 280 nm). G4 PAMAM 
dendrimers were dissolved in a citrate buffer. 
Double-distilled water served as a solvent. In tests with 
Ag+ ions, chemically pure AgNO3 was used and Tris buffer 
or NaNO3 served as background electrolyte. For the 
reduction of silver ions, ascorbic acid (AA) was used. We 
have used molar extinction coefficient for silver atom 
ɛ=7160 cm-1 M-1 at λ = 430 nm. 
The measurement of absorption spectra was carried out by 
compact, precessive, mobile, small-power consuming 
optical fiber spectrometer AvaSpec ULS 2048-USB2. As a 
source of light we used a deuterium lamp in the ultraviolet 
region and quartz halogen incandescent lamp in the visible 
region. 
Data collection, processing and visualization were carried 
out by CCD, connected to a personal computer and special 
computer programs, experimental results were processed by 
Origin software. 
RESULTS AND DISCUSSION 
The Ag+ ions reduction process in drug delivery 
nanoparticles, G4 PAMAM dendrimers, was studied. Figure 
2 depicts absorption spectra of the silver atoms obtained 
from the reduction of silver ions in G4 PAMAM dendrimers, 
induced by ascorbic acid (AA).  
 
 
 
 
 
 
 
 
Figure 2. Time dependent absorption spectra of Ag+ reduction in 
G4-Ag+-AA complex. [G4] = 1.4 x 10-4 M, [AgNO3] = 1.2 x 10-4 M, 
[AA] = 2.4 x 10-4 M. 
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Therefore, using the unique features of G4 PAMAM 
dendrimers, new, stable, nanosized (∼5 nm) complexes with 
9-10 silver atoms, which have strong absorption in the 
visible area that make them eligible for use in nanomedicine, 
were created. 
Figure 3 represents the kinetic curve of the reduction 
process of silver ions in G4 PAMAM dendrimers. The linear 
relationship shows that simple diffusion takes place (eqn. 1). 
Mt/Me = 2(Dt/ π)1/2 [cm/s1/2]     (1) 
where Mt = the number of ions have been absorbed at t, Me = 
the number of ions in equilibrium (saturation in optical 
absorption). 
It also shows that G4 PAMAM dendrimer does not change 
conformation during the formation of a nanocomplex with 
silver atoms.  
 
 
 
 
 
 
 
 
Figure 3. Kinetic curve of Ag+ ions reduction in G4 dendrimers.  
Figure 4 is a schematic representation of the model of the 
formation of the nanocomplex of G4 (NH2)64 PAMAM 
dendrimers with a silver atoms. The creation of 
nanocomplexes is a process consisting of two simple 
processes. 
 
 
 
 
Figure 4. Model of creation of metal encapsulated G4 PAMAM 
dendrimers: reduction of silver ions to an atomic state in G4 
PAMAM dendrimers. 
It should be noted that the results presented in Figure 2 
and 3 are of great spectroscopic interest. We have one G4 
PAMAM dendrimer per 9-10 reduced silver atoms, and the 
absorption spectra show that the silver atom inside the 
dendrimer cavity is in the hydrated state. It should be noted 
that Ag+ ions in solutions are in an octahedral complex. 
Table 1. Wavelengths of the maximum and full width at half 
maximum of the of the absorption spectra of silver atoms in 
different conditions. 
Material 
 
λmax, nm Full width at half 
maximum, nm 
AgNPs 431 140 
AgNPs - DNA 425 133 
Ag+-DNA-AA after 10 
 
462 294 
G4-Ag+-AA after 2 days 425 146 
 
The location of the absorption maximum of silver atom (λ 
= 425 nm) indicates that the silver atom Ag0 in G4 PAMAM 
dendrimer is in aqueous environment, i.e., that it is not 
connected to the polymer with a chemical or coordinate 
bond. This is the absorption maximum for the silver atom in 
a water environment with the shortest wavelength (Table 1). 
The diffusion of ascorbic acid molecule in G4 PAMAM 
dendrimer has a linear characteristic that indicates that the 
polymer molecule does not undergo the conformational 
changes.  
Table 1 presents the wavelength of the maximum and full 
width at half maximum of the of the absorption spectra of 
silver atoms in AgNPs, AgNPs-DNA complex, Ag+-DNA 
complex after the reduction of Ag+ by AA, and Ag+-G4 
PAMAM dendrimer complex after the reduction of Ag+ by 
AA. From the data presented in the table, it is clear that the 
shortest wavelength of absorption has the silver atoms 
incorporated into the G4 PAMAM dendrimer. The stronger 
the chromophore interacts with neighboring groups, the 
stronger the bathochromic shift.45 Thus it may be concluded 
that the strongest interaction the silver atoms undergo are 
connected with the linear coordination between the DNA 
chains (inter strand croslink). It should be noted that linear 
coordination is characteristic of soft acids, namely Ag+, Ag0, 
Cu+, Pt2+, Hg2+. In an earlier work,46  it was shown that the 
interaction of AgNPs with DNA leads to wetting of small-
sized AgNPs with hydrated surface of DNA.  
Figure 5 shows the scheme of irradiation of silver atoms 
encapsulated in dendrimers (λ= 425 nm) which will lead to 
excitation of silver atoms and the dissipation of energy on 
water molecules that will cause electrolytic dissociation of 
water molecules on H+ and OH-, which is the necessary 
condition for hydrolysis of amide groups (HNCO) of G4 
PAMAM dendrimer. 
 
 
 
 
 
 
Figure 5. Scheme of energy levels corresponding to silver atom 
encapsulated in the G4 PAMAM dendrimer and high frequency 
vibration of water molecules (singlet-singlet energy transfer from 
donor to acceptor). 
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It should be noted that the excited silver atom does not 
have fluorescence in aqueous solutions, and therefore the 
complete dissipation of excited energy takes place on the 
water molecules. 
Since the high-frequency vibration spectrum of the 
overtones of XH groups, including the OH groups of water 
molecules, can be easily observed in the near infrared and 
visible region,47 the resonant interaction between the 
radiating oscillator (for example Ag0) and the high-
frequency overtones oscillator in the region of ΔE>>hνosc 
(2.9 eV>>0.364 eV) is present. ΔE is excitation energy of 
Ag0 and hνosc is quantum of vibrational energy for normal 
oscillation of valence bond of water molecule. 
Figure 6 schematically represents the hydrolysis of amide 
groups near the silver atom as a result of irradiation of silver 
atom encapsulated in G4 PAMAM dendrimer. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Hydrolysis of amide group in G4 PAMAM 
dendrimerdue caused by the irradiation of Ag0 atom encapsulated 
in dendrimer. 
The absorption spectra of the reduction of silver ions in 
the complex with the DNA, induced by the reductant AA is 
presented in figure 7. We added AA to the DNA–Ag+ 
complex to reduce the silver ions to atoms (Ag+→Ag0). 
Silver ions (Ag+) do not absorb in near ultraviolet or visible 
area, while the silver atoms (Ag0) absorb in visible area, so 
we have the possibility to observe the reduction process.  
The reduction of silver ions is a long process and, in about 
160 min, we can clearly observe the appearance of 
absorption spectrum at λ = 464 nm, and in 24 h absorption 
spectra specific for silver atoms can be observed.  
We can see that the absorption spectra have a complex 
form. They resemble the absorption spectra of substances 
that have specific resonance interactions. Resonance 
interactions are specific for structures that have identical 
chromophore and hard structure,48 for example, a similar 
structure of absorption spectra is characteristic for 
polypeptide in α-helix state, where the chromophore is the 
peptide group.49 Also the reason for the complicated 
absorption spectra is the interaction of silver ions, which is 
characterized by inter-cross type of links with DNA, which 
reduces dynamic characteristics of double helix and makes it 
harder.  
 
 
 
 
 
 
 
 
Figure 7. Time dependent absorption spectra of reduction of Ag+ 
ion Ag0 atom in DNA-Ag+-AA complex. [DNA] = 5.9 x10-4 M(P), 
[AgNO3] = 1.2 x 10-4 M, [AA] = 2.4 x 10-4 M, [NaNO3] = 10-2 M. 
Figure 8 represents kinetics curve of Ag+ ions reduction 
on DNA, it shows, that curve is sigmoidal, which means that, 
unlike G4 PAMAM dendrimers (Figure 3), DNA changes 
conformation during the reduction of silver ions. 
 
 
 
 
 
 
 
 
Figure 8. Kinetic curve of reduction of Ag+ ions on DNA. Mt = the 
number of ions have been absorbed at t time, Me = the number of 
ions at saturation. 
For phototherapy, we suggest the nanocomplex of silver 
atoms encapsulated in the G4 PAMAM dendrimer, which 
should be able to penetrate cell membrane and more 
importantly cell nucleus, the size of pores in nucleus 
membrane is 8-9 nm. The created complexes have 
absorption in visible area λ = 425 nm. Irradiation at the 
frequency of their absorption will lead to excitation of silver 
atoms and the dissipation of energy on water molecules that 
will cause electrolytic dissociation of water molecules on H+ 
and OH-, which is the necessary condition for hydrolysis of 
amide groups of G4 PAMAM dendrimer. Finally, the silver 
atoms released from G4 PAMAM dendrimer interact with 
DNA, which is a powerful toxic method for the destruction 
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of cells and in case of cancer cells it can be a potential 
medication for photo chemotherapy (see Figure 9). 
 
 
 
 
 
 
 
 
 
 
Figure 9. A schematic  presentation of nanocomplex (silver atom 
encapsulated in G4 PAMAM dendrimer) entry in cell membrane 
through endocytosis, entry in nucleus from cytoplasm, irradiation 
of complex (λ=425 nm) and interaction of released silver atom 
with DNA. 
It should be noted that the new potential medication 
proposed by us (silver atom encapsulated in G4 PAMAM 
dendrimer) has low toxicity to life, since the free silver atom 
is oxidized to a silver ion and silver ions form insoluble salts 
with chloride ions, the number of which is high in the body, 
and finally, the removal from the body occurs by fecal 
masses.50 The irradiation of silver atom encapsulated in G4 
PAMAM dendrimer and the influence of released silver 
atom on DNA will be studied experimentally in the future. 
CONCLUSIONS  
Silver ions reduction process in drug delivery 
nanoparticles, G4 PAMAM dendrimers, has been studied. 
Using the unique features of PAMAM dendrimers, new, 
stable, nanosized (∼5 nm) complexes with 9-10 silver atoms 
in each dendrimer are created. Silver ions reduction process 
on DNA has been studied, and it has been shown that 
interaction of DNA with Ag0 atoms cause conformational 
changes, which in the living organism is the precondition for 
cell damage. For phototherapy, we suggest the nanocomplex 
of silver atoms encapsulated in the G4 PAMAM dendrimer, 
which should be able to overcome the cell membrane and 
cell nucleus, the size of pores in nucleus membrane is 8-9 
nm.  
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INTRODUCTION  
N-Alkoxy-N’,N’,N-trimethylhydrazinium salts (1) are 
stable1,2 derivatives of unstable N-alkoxyhydrazines3-10 and 
they have a unique structure. N-Methoxy-N’,N’N’-
trimethylhydrazinium perchlorate has the longest N–N+ 
bond [1.483(30Å]2 and a very short N–OMe bond [1.391(3) 
Å].2 
Normally, some types of N-alkoxyhydrazines such as N-
alkoxy-N-alkylamines3,5 and N-alkoxy-N-aminoamides4,6-10 
are destabilized by the nN’→σ*N-O(R) orbital interaction 
(“anomeric effect”).6-10 Usually, the N-alkoxy-N-chloro-N-t-
alkylamines interaction with amines gives unstable N-
alkoxyhydrazines which eliminate a molecule of alcohol 
yielding the proper diazenes3 (Scheme 1). Only one single 
relatively stable N-alkoxyhydrazine (2) has been obtained 
but it is converted into diazene (3) by an action of 
methanol.3 
N-Alkoxy-N-chloro derivatives of amines3,5 and amides1-
4,11-15 selectively give stable N-alkoxyamino-pyridinium salts 
(4) by interacting with pyridines (Scheme 2). 3,5,11-17 
However the N-alkoxy-N’,N’,N-trialkylhydrazinium salts 
(1,5)1,2 are formed only during the reaction of N-alkoxy-N-
chloroureas with trimethylamine and 1,4-
diazabicyclo[2.2.2]octane (Scheme 3). The stability of the 
N-alkoxy-N’,N’,N-trialkylhydrazinium salts (1,5)1,2 as well 
as the 1-N-alkoxyamino-pyridinium salts (4)3-5,11-17 is based 
on the inability of nN’→σ*N-O(R) anomeric effect due to the 
absence of the lone electron pair in N’ nitrogen atom. The 
mechanism of generation of N-alkoxy-N’,N’,N-
trialkylhydrazinium salts (1,5) is unknown but it may be 
presumed that at the first stage the labile product of 
nucleophilic substitution at the nitrogen atom (6,7) is formed. 
Then, the intermediates 6,7 are decarbamoylated by the 
action of excess amine. In a similar way the 
decarbamoylation in the presence of bases of the N-
alkoxyaminopyridinium salts (4b) (or N-alkoxy-N-(4-
dimethylaminopyridin-1-ium-yl)urea chlorides) produces 1-
alkoxyaminopyridinium chlorides.14,17 
The aim of our investigation is to study the possibility of 
synthesis of N-alkoxy-N’,N’,N-trimethylhydrazinium 
chlorides (1) from methyl N-alkoxy-N-chlorocarbamates 
(8a-f) and ethyl N-chloro-N-methoxycarbamate (9). 
EXPERIMENTAL  
1H NMR spectra were recorded on the 300 MHz VARIAN 
VXR-300 and the 400 MHz VARIAN JEMINI 400 
spectrometers. 13C NMR spectra were recorded on a Varian 
VXP-300 spectrometer (75 MHz). 1H NMR chemical shifts 
were reported relative to the residual solvent protons as an 
internal standard ((CD3)2SO: 2.50 ppm) or with Me4Si as an 
internal standard (in CDCl3). Solvent carbon atoms served 
as an internal standard for 13C NMR spectra ((CD3)2SO: 
39.52 ppm). Mass spectrum was recorded on VG 770-70EQ 
spectrometer in FAB regime. The solvents were purified and 
dried according to the standard procedures.  
N-Methoxy-N’,N’N’-trimethylhydrazinium chloride (1a)  
Method A: A solution of trimethylamine (3.735 mmol, 
221 mg) in MeCN (3 mL) was added to a solution of methyl 
N-chloro-N-methoxycarbamate18 (8a, 3.216 mmol, 449 mg) 
in MeCN (7 mL) at -29 °C, the reaction mixture was heated 
to 14 °C during 21 h, then the negligible precipitate formed 
was filtered off, the MeCN-filtrate was evaporated under 
vacuum (25 mm Hg), benzene (10 mL) was added, the 
mixture was kept at 5 °C for 4 days, then the benzene phase 
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was decanted from obtained solid residue. The solid residue 
was washed by benzene (3mL), dried under vacuum 2 mm 
Hg, dissolved in MeCN and precipitated by EtOAc (2:1), 
dried under vacuum (2 mmHg), giving N-methoxy-N’,N’N’-
trimethylhydrazinium chloride (1a) as colorless hygroscopic 
crystals (49 mg, 11 %). 1Н NMR (300 MHz, (СD3)2SO) δ 
=3.239 (9H, s, Me3N+), 3.740 (3H, s, NOMe), 10.404 (1H, s, 
NH). 13C NMR (75 MHz, (СD3)2SO) δ = 50.39 (Me3N+), 
64.71 (NOMe). MS (FAB, m/z, Irel, (%)): 105 M+ (65), 74 
(100).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. The formation of diazenes as the result of N-alkoxy-N-chloro-N-tert.-alkylamines interaction with amines.  
 
 
 
 
 
 
Scheme 2. The formation of N-alkoxyaminopyridinium salts (4a-f) from N-alkoxy-N-chloro compounds by an interaction with the 
pyridines. 
 
 
 
 
 
 
 
 
 
Scheme 3. The earlier reported synthesis of the N-alkoxy-N’,N’,N-trialkylhydrazinium salts (1,5). 
N
MeO
Cl
Me
MeO2C
Me
N
MeO NHR
Me
MeO2C
Me
RNH2 - MeOH
N
N
Me
MeO2C Me
R
RNH2
- MeOH
N
N
Me
C Me
R
RHN
O
R = Me, Et
N
MeO Cl
Me
MeO2CH2C
Me
HN N
MeO
N
Me
MeO2CH2C
Me
- MeOH
N
N
Me
MeO2CH2C Me
H
C
CH2
2 3
HN
CMe2
- MeOH
N NMe
MeO2CH2C
Me
C CH2Cl
Me
Me
N Cl
AlkO
R
+ N X N XN
AlkO
R Cl
4a-f
R = t-Alk' (a), C(O)NH2 (b), C(O)NMe2 (c), CO2Et (d), C(O)Ph (f)
X = H, NMe2
N
ClRO
OH2N
Me3N
N NMe3
RO
O
H2N
Cl
- HNCO
N NMe3
RO
H
Cl
6 1
N
N
N
N
N
RO
NH2
O
Cl
7
- HNCO N
N
NH
Cl
RO
5
R = Me, Et, n-Bu, Bn
N-Alkoxy-N’,N’,N’-trimethylhydrazinium chlorides          Section A-Research paper 
Eur. Chem. Bull., 2020, 9(1), 28-32   http://dx.doi.org/10.17628/ecb.2020.9.28-32 30 
From MeCN–EtOAc phase after evaporation under 
vacuum and crystallization compound (1a) (199 mg, 44 %) 
was obtained additionally.  
The benzene extract was evaporated under vacuum (20 
mm Hg), the residue was maintained at 4 mm Hg giving 
N,N’-dimethoxy-N,N’-di(methoxycarbonyl)hydrazine (10a) 
as white crystals (51 mg, 15 %), mp 52–53°C (hexane), 
which was identified by1Н NMR spectra and mass 
spectrum.2,18 1Н NMR (300 MHz, СDCl3) δ = 3.891 (12H, s, 
NOMe, CO2Me).  1Н NMR (400 MHz, СDCl3) δ = 3.902 
(6H, s, NOMe), 3.916 (6H, s, CO2Me). MS (FAB, KI, m/z, 
Irel, (%)): 247 [M+K]+ (100). 
Method B: A solution of trimethylamine (4.284 mmol, 
253 mg) in MeCN (5 mL) was added to a solution of ethyl 
N-chloro-N-methoxycarbamate19 (9) (2.108 mmol, 324 mg) 
in MeCN (5 mL) at -30 °C, the reaction mixture was heated 
to 18 °C for 22 h, then the negligible precipitate formed was 
filtered off, the MeCN-filtrate was evaporated under 
vacuum (20 mm Hg), the residue was washed by Et2O (10 
mL), the residue was dissolved in MeCN (4 mL) and 
benzene (8 mL) was added. The precipitated viscous oil was 
separated from PhH–MeCN phase, dried under vacuum (2 
mm Hg), giving N-methoxy-N’,N’N’-trimethylhydrazinium 
chloride (1a) as colorless hygroscopic crystals (143 mg, 
48 %) which was identified by 1H and 13C MR spectra, and 
MS spectrum.  
The Et2O-extact was evaporated under vacuum (20 mm 
Hg), the residue was washed by CCl4 (5 mL) for 40 h, then 
it was separated and dried under vacuum (2 mm Hg), giving 
1a (125 mg, 42 %) additionally.  
1-N-Ethoxy-N’,N’N’-trimethylhydrazinium chloride (1b)  
A solution of trimethylamine (2.487 mmol, 147 mg) in 
MeCN (2 mL) was added to a solution of methyl N-chloro-
N-ethoxycarbamate20 (8b) (1.370 mmol, 210 mg) in MeCN 
(5 mL) at -15 °C, the reaction mixture was kept at -15 °C for 
2 h and at 5 °C for 20 h. The negligible precipitate was then 
filtered off, the MeCN-filtrate was evaporated under 
vacuum (15 mm Hg), the residue was washed by Et2O (5 
mL) and dried at 2 mm Hg, giving N-ethoxy-N’,N’N’-
trimethylhydrazinium chloride (1b) as white hygroscopic 
solid (209 mg, 98 %). 1Н NMR (300 MHz, (СD3)2SO) δ = 
1.192 (3H, t, 3J=6.9 Hz, NOCH2Me), 3.253 (9H, s, Me3N+), 
3.900–4.050 (2H, m, NOCH2Me), 10.334 (1H, s, NHO). 13C 
NMR (75 MHz, (СD3)2SO) δ = 13.76 (Me), 50.27 (Me3N+), 
72.24 (OCH2). MS (FAB, m/z, Irel, (%)): 275 [2M•Cl]+(6), 
273 [2M•Cl]+(18), 119 M+ (100), 73(73). 
N-n-Propyloxy-N’,N’N’-trimethylhydrazinium chloride (1c)  
A solution of trimethylamine (2.739 mmol, 162 mg) in 
MeCN (2 mL) was added to a solution of methyl N-chloro-
N-n-propyloxycarbamate (8c) (1.996 mmol, 336 mg) in 
MeCN (5 mL) at -25 °C, the reaction mixture was heated to 
-14 °C for 1 h, then it was maintained at 15 °C for 24 h and 
the negligible precipitate was filtered off. The MeCN-
solution was evaporated under vacuum (20 mm Hg), the 
residue was dried at 2 mm Hg, washed by benzene (10 mL), 
dried under vacuum( 2 mm Hg) and giving N-n-propyloxy-
N’,N’N’-trimethylhydrazinium chloride (1c) as white 
hygroscopic solid (178 mg, 53 %). 1Н NMR (400 MHz, 
(СD3)2SO) δ = 0.895 (3H, t, J=7.2 Hz, NO(CH2)2Me), 
1.499–1.613(2H, m, NOCH2CH2Me), 3.252 (9H, s, Me3N+), 
3.788–3.865 (1H, m, NOCH2), 3.886–3.958 (1H, m, 
NOCH2), 10.438 (1H, s, NHO). 13C NMR (100 MHz, 
(СD3)2SO) δ=10.14 (NO(CH2)2Me), 21.46 (NOCH2CH2Me), 
50.31 (Me3N+), 78.12 (NOCH2). MS (FAB, m/z, Irel, (%)): 
303 [2M+•Cl-] (4), 301 [2M+•Cl-] (13), 133 M+ (100), 73(35), 
56(37).  
N-n-Butyloxy-N’,N’N’-trimethylhydrazinium chloride (1d)  
A solution of trimethylamine (2.490 mmol, 147 mg) in 
MeCN (3 mL) was added to a solution of methyl N-n-
butyloxy-N-chlorocarbamate20,21 (8c) (1.663 mmol, 302 mg) 
in MeCN (4 mL) at -30 °C, the reaction mixture was heated 
to 15 °C for 18 h and the negligible precipitate was filtered 
off. The MeCN-filtrate was evaporated under vacuum (20 
mm Hg), the residue was washed by benzene (10 mL), dried 
under vacuum (4 mm Hg) and extracted by CH2Cl2 (10 mL). 
The CH2Cl2-extract was evaporated under vacuum (20 mm 
Hg), the residue was extracted by acetone (3 mL), Me2C(O)-
extract was evaporated under vacuum and dried at 4 mm Hg, 
giving N-n-butyloxy-N’,N’N’-trimethylhydrazinium chloride 
(1d) as viscous yellowish oil (151 mg, 50 %). 1Н NMR (400 
MHz, (СD3)2SO) δ = 0.899 (3H, t, 3J=7.2 Hz, 
OCH2CH2CH2Me), 1.357 (2H, sex, 3J=7.2 Hz, 
OCH2CH2CH2Me), 1.545 (2h, quint, 3J=7.2 Hz, 
OCH2CH2CH2Me), 3.217 (9H, s, Me3N+), 3.781–3.913 (1H, 
m, NOCH2), 3.950–4.035 (1H, m, NOCH2), 10.129 (1H, s, 
NHO). 13C NMR (75 MHz, (СD3)2SO) δ = 13.75 (Me), 
18.48, 30.19 (CH2), 50.41 (Me3N+), 76.53 (NOCH2). MS 
(FAB, m/z, Irel, (%)): 331 [2M•Cl]+(1.5), 329 [2M•Cl]+(5), 
147 M+ (100), 57 Bu+ (48). 
N-Benzyloxy-N’,N’N’-trimethylhydrazinium chloride (1e)  
A solution of trimethylamine (2.856 mmol, 169 mg) in 
MeCN (2 mL) was added to a solution of methyl N-
benzyloxy-N-chlorocarbamate18 (8e) (1.454 mmol, 314 mg) 
in MeCN (5 mL) at -15 °C, the reaction mixture was heated 
to 5 °C for 2h, was kept at 5 °C for 20 h, then it was 
evaporated under vacuum (15 mm Hg), the residue washed 
by Et2O (7 mL), dried at 2 mm Hg, giving N-benzyloxy-
N’,N’N’-trimethylhydrazinium chloride (1e) as hygroscopic 
white solid (256 mg, 86 %). 1Н NMR (300 MHz, (СDCl3) 
δ=3.409 (9H, s, Me3N+), 4.880 (1H, d, 2J=10.5 Hz, 
NOCH2Ph), 4.943 (1H, d, 2J=10.5 Hz, NOCH2Ph), 7.342 
(5H, s, Ph); 10.963 (1H, s, NHO). 1Н NMR (300 MHz, 
(СD3)2SO) δ = 3.314 (9H, s, Me3N+), 4.86–5.14 (2H, m, 
NOCH2Ph), 7.31–7.45 (5H, m, Ph), 10.629 (1H, s, NHO). 
13C NMR (75 MHz, (СD3)2SO) δ = 50.52 (Me3N+), 78.34 
(NOCH2), 128.31 [C(4) Ph], 128.39, 128.41 [C(2,4) and 
C(3,5) Ph], 135.92 [C(1) Ph]. MS (FAB, m/z, Irel, (%)):181 
M+ (100), 91(55), 74 (53). 
N-n-Octyloxy-N’,N’N’-trimethylhydrazinium chloride (1f)  
A solution of trimethylamine (2.988 mmol, 177 mg) in 
MeCN (2 mL) was added to a solution of methyl N-chloro-
N-n-octyloxycarbamate19 (8f) (0.979 mmol, 233 mg) in 
MeCN (5 mL) at -17 °C, the reaction mixture was heated to 
11 °C for 21 h, then it was evaporated under vacuum (15 
Hg), the residue was extracted by CH2Cl2 (8 mL), the 
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negligible solid was filtered off. The CH2Cl2-extract was 
evaporated under vacuum (20 mm Hg), the residue was 
dissolved in benzene (6 mL), and hexane (12 mL) was 
added. The precipitated liquid phase was separated, washed 
by hexane (4 mL), dried under vacuum (2 mm Hg) giving 
N-n-octyloxy-N’,N’N’-trimethylhydrazinium chloride (1f) as 
colorless hygroscopic solid (89 mg, 38 %). 1Н NMR (300 
MHz, СDCl3) δ = 0.855 (3H, t, J=6.9 Hz, NO(CH2)7Me), 
1.159–1.368 (10H, m, NOCH2CH2(CH2)5Me), 1.553–1.664 
(2H, m, NOCH2CH2(CH2)5Me), 3.494 (9H, s, Me3N+), 3.911 
(2H, t, J=6.3 Hz, NOCH2), 10.721 (1H, s, NHO). 1Н NMR 
(300 MHz, (СD3)2SO) δ = 0.850 (3H, t, J=6.3 Hz, 
NO(CH2)7Me), 1.204–1.344 (10H, m, 
NOCH2CH2(CH2)5Me), 1.489–1.604 (2H, m, 
NOCH2CH2(CH2)5Me), 3.248 (9H, s, Me3N+), 3.816–3.911 
(1H, m, NOCH2), 3.952–4.029 (1H, m, NOCH2), 10.413 
(1H, s, NHO). 13C NMR (75 MHz, (СD3)2SO) δ = 13.90 
(Me), 22.04, 25.17, 28.08, 28.58, 28.75, 31.19 (CH2), 50.37 
(Me3N+), 76.78 (NOCH2). MS (FAB, m/z, Irel, (%)): 443 
[2M+•Cl-]+ (2), 441 [2M+•Cl-]+(6), 203 M+ (100).  
RESULTS AND DISCUSSION 
It has been found that methyl N-chloro-N-
methoxycarbamate (8a) interacts with an excess of 
trimethylamine in MeCN forming of N-methoxy-N’,N’N’-
trimethylhydrazinium chloride (1a) as the main  product 
(Scheme 4). Also, N,N’-dimethoxy-N,N’-
di(methoxycarbonyl)hydrazine (10a) has been obtained as 
by-product in a relatively small yield. Ethyl N-chloro-N-
methoxycarbamate (9) reacts with trimethylamine in MeCN 
producing N-methoxy-N’,N’N’-trimethylhydrazinium 
chloride (1a) (Scheme 4). 
 
 
 
 
 
 
 
Scheme 4. Synthesis of N-methoxy-N’,N’N’-trimethylhydrazinium 
chloride 1a from methyl (8a) and ethyl (9) N-chloro-N-
methoxycarbamates. 
 
In a similar manner methyl N-alkoxy-N-chlorocarbamates 
(8b-f) react with trimethylamine yielding N-alkoxy-
N’,N’N’-trimethylhydrazinium chlorides (1b-f) (Scheme 
5).The structure of the synthesized N-alkoxy-N’,N’N’-
trimethylhydrazinium chlorides (1a-f) has been confirmed 
by data of 1H and 13C NMR spectra and mass spectra.  
In 1H NMR spectra of compounds 1a-f the characteristic 
chemical shifts of hydrogen atoms of Me3N+ group are 
observed at 3.2 – 3.3 ppm, and protons of NHO group in a 
low field are observed at 10.1 – 10.6 ppm (Table 1). 
 
 
 
 
Scheme 5. Synthesis of N-alkoxy-N’,N’N’-trimethylhydrazinium 
chlorides 1b-f. 
Table 1. The characteristic 1H NMR chemical shifts of N-alkoxy-
N’,N’N’-trimethylhydrazinium chlorides (1a-f) in (CD3)2SO. 
R Resonance, σ, ppm 
Me3N+ NHO 
Me (1a) 3.239 10.404 
Et (1b) 3.253 10.334 
Pr (1c) 3.252 10.438 
n-Bu (1d) 3.217 10.129 
PhCH2 (1e) 3.314 10.629 
n-C8H17 (1f) 3.248 10.413 
Table 2. The characteristic 13C NMR chemical shifts of N-alkoxy-
N’,N’N’-trimethylhydrazinium chlorides (1a-f) in (CD3)2SO 
R Resonance, σ ppm 
Me3N+ NOCH2 
Me (1a) 50.39 64.71(Me) 
Et (1b) 50.27 72.24 
Pr (1c) 50.31 78.12 
n-Bu (1d) 50.41 76.53 
PhCH2 (1e) 50.52 78.34 
n-C8H17 (1f) 50.37 76.78 
In 13C NMR spectra of compounds 1a-f the characteristic 
chemical shifts of carbon atoms of Me3N+ group are 
observed at 50.3 – 50.5 ppm and NOCH2 group at 72.2 – 
78.3 ppm (Table 2). In the mass spectra the signals of M+ 
ion are present. The signals of [2M•Cl]+ ions are often 
observed as well. As the mechanism of compounds 1a-f 
formation remains unclear, one may assume that it occurs in 
two stages (Scheme 6). At the first stage the unstable 
intermediates (11a-f) are formed by nucleophilic 
substitution at the nitrogen atom in N-alkoxy-N-
chlorocarbamates 8,9 (Scheme 6). Then the intermediates 
11a-f produce N-alkoxy-N’,N’N’-trimethylhydrazinium 
chlorides (1a-f) by the methoxycarbonyl group elimination. 
 
 
 
 
Scheme 6. The possible route of N-alkoxy-N’,N’N’-
trimethylhydrazinium chlorides 1a-f formation
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This reaction is a new kind of the synthesis of N-alkoxy-
N’,N’N’-trimethylhydrazinium chlorides (1a-f), which 
confirms that this type of reactions can be performed. 
CONCLUSIONS 
It has been found that the synthesis of N-alkoxy-N’,N’,N-
trimethylhydrazinium chlorides by the N-alkoxy-N-
chlorocarbamates interaction with trimethylamine is 
possible. 
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GREEN SYNTHESIS OF QUINOXALINE DERIVATIVES AT 
ROOM TEMPERATURE IN ETHYLENE GLYCOL WITH 
H2SO4/SiO2 CATALYST  
Mozhgan Bashirzadeh[a] and Farahnaz K. Behbahani[a]* 
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In this study, the preparation of quinoxaline derivatives using α-diketones, 1,2-phenylene diamines in the presence of H2SO4/SiO2 catalyst 
in ethylene glycol and at room temperature is reported. The advantages of this method are high yields of the products, utilizing of reusable 
catalyst, easy separation and mild reaction conditions. Also, reusability of the catalyst was investigated and found that catalytic activity of 
the catalyst did not decreased after 4th times.  
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INTRODUCTION 
Quinoxaline derivatives are well known in the 
pharmaceutical industry and have been shown to have a 
broad spectrum of biological activities including 
antibacterial, antiviral, anti- inflammatory, anticancer, and 
kinase inhibitory activities. 1,2 In addition, quinoxaline 
derivatives have been evaluated as semiconductors, dyes, 
and biocides.3 In this regards, a very procedures have 
respectively been developed for the preparation of 
substituted quinoxalines.4,5  
In these methods the condensation reaction between an 
aryl 1,2-diamine with a 1,2-dicarbonyl compound have been 
reported4. The others synthetic routes towards quinoxalines, 
including oxidative coupling of epoxides with ene-1,2-
diamines using Bi-catalyst, heteroannulation of nitroketene 
and N,S-aryliminoacetals with POCl3, cyclization of a-
arylimino oximes of α-dicarbonyl compounds and from α-
hydroxy ketones via a tandem oxidation process using 
Pd(OAc)2 or RuCl2-(PPh3)3-TEMPO as well as MnO2.5  
Most of the existing methodologies suffer from 
disadvantages such as the use of volatile organic solvents, 
unsatisfactory product yields, critical product isolation 
procedures, expensive and detrimental metal precursors and 
harsh reaction conditions, which limit their use under the 
aspect of environmentally benign processes. Also silica-
supported reagent, H2SO4 / SiO2 for its ease of preparation, 
low cost, high efficiency and environmental benignness,6 
has already been used in cylcoadditions,7 Beckmann 
rearrangements,8 glycosylations,9 condensations,10  
esterification,11 acetylation of (+)cedrol compound,12 
synthesis of 2,4,5-triaryl-1H-imidazoles,13 and as catalyst in 
organic transformations: a comprehensive review.14  
On the other hand, during our continuing efforts to 
develop convenient approaches to synthesize heterocycle 
compounds,15 we revealed that H2SO4/SiO2 was a high-
efficient and recyclable catalyst for preparing the 
quinoxaline derivatives in a synthetically practical 
procedure (stoichiometric ratios of starting materials and 
short reaction times) with relatively widely functional group 
compatibility in ethylene glycol at ambient temperature 
(Scheme 1). 
 
 
 
 
 
Scheme 1 Synthesis of quinoxaline derivatives in the presence of 
H2SO4 /SiO2 
RESULTS AND DISCUSSION 
To achieve efficient amount of catalyst, the author set up a 
model reaction using benzil (2.0 mmol), and 1,2-phenylene 
diamine (2.0 mmol) in ethylene glycol (3.0 ml) without 
catalyst at room temperature. In this case, the product was 
obtained in low yield (30%). As shown in table 1, the yield 
of reaction was increased in the presence of the catalyst (0.1 
- 0.3 g) and raising catalyst amount toward 0.4 g did not 
affect to reaction yield.  
Table 1. Optimizing of the catalyst amount for the synthesis of 
quinoxaline derivatives 
Yield%a Catalyst g 
30 Free 
50 0.1 
55 0.2 
92 0.3 
92 0.4 
aReaction condition: Benzyl (2.0 mmol), 1,2-phenylenediamine 
(2.0 mmol) and catalyst in ethylene glycol (3.0 ml) at room 
temperature 
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When we examined model reaction (entry1, table 2) in the 
presence of SiO2, the desired product was obtained in very 
low yield (< 10 %), but the product was resulted in 90% 
using H2SO4 in similar condition as well as sulfuric 
acid/SiO2 combination. Therefore, we decided to use 
sulfuric acid/SiO2 combination due to its safe, to be solid 
and its reusability than H2SO4 alone that is dangers and 
corrosive.  
To evaluate the efficiency of this methodology, a number 
of 1,2-dicarbonyl compounds and 1,2-diamines were further 
subjected to condensation using very low amount of H2SO4 / 
SiO2  (Table 2). When the electron-donating substituents 
present in diamine part, decreased reaction time, whereas 
the effect is reverse with the electron withdrawing 
substituents.  
 
 
Table 2. Synthesis of quinoxaline derivatives in the presence of H2SO4/SiO2 in ethylene glycol 
1,2-Diketone Amine Product Time, h Yield, % m.p., °C  
O
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On the other hand, electron-donating substituents with 
aromatic 1,2-diketone increased reaction time and the effect 
is reverse with electron withdrawing groups. 
Proposed mechanism for the preparation of quinoxaline 
derivatives in the presence of H2SO4/SiO2 has been shown in 
Scheme 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Suggested mechanism for the synthesis of quinoxaline derivatives using H2SO4/SiO2 
 
 
EXPERIMENTAL 
Melting points were measured by using the capillary tube 
method with an electro thermal 9200 apparatus. IR spectra 
were recorded on Perkin Elmer FT-IR spectrometer did 
scanning between 4000–400 cm–1. 1H NMR spectra were 
obtained on Bruker DRX-300MHz NMR instrument in 
CDC13. Analytical TLC of all reactions was performed on 
Merck precoated plates (silica gel 60F-254 on aluminum). 
All compounds are known and spectra and physical data 
were compared with those of authentic samples.16-19 The 
catalyst was prepared according to the reported procedure in 
the literature.20 
Preparation of quinoxaline derivatives using H2SO4/SiO2: 
general procedure: 
To a mixture of an appropriate o-phenylenediamine (1 
mmol, 0.108 g ) and a 1,2-dicarbonyl compound (1 mmol) 
in ethylene glycol (3 ml), a catalytic amount of H2SO4/SiO2 
(0.3 g) was added and the mixture was stirred at room 
temperature. The progress of the reaction was monitored by 
TLC (ethyl acetate:n-hexane, 1:3). After completion of the 
reaction, chloroform (10 ml) was added to the solidified 
mixture in order to separation of catalyst from the mixture 
since the catalyst is not soluble in organic solvent. The 
residue was then diluted with H2O (15 mL) and the product 
was extracted with chloroform (2 × 10 mL). The combined 
organic layers was dried over Na2SO4. The solvent was 
evaporated under reduced pressure and the pure product was 
obtained without any further purification.  
A variety of substituted o-phenylenediamines were 
condensed with different 1,2-dicarbonyl compounds. The 
results are shown in Table 2. 
2,3-Diphenylquinoxaline  
White solid, IR (KBr, cm-1): 3055, 1541, 1495, 1477, 
1441, 1346, 1315. 1 H NMR (CDCl3, 300 MHz): 8.16-8.20 
(m, 2H), 7.76 -7.79 (m, 2H), 7.56-7.50 (m, 4H), 7.25-7.29 
(m, 6H). 
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6-Methyl-2,3-diphenylquinoxaline 
Light yellow solid, IR (KBr, cm-1): 3055, 2941, 1619, 
1554, 1485, 1444, 1393, 1344. 1H NMR (CDCl3, 300 MHz): 
2.63 (s, 3H), 7.25-7.35 (m, 5H), 7.45-7.55 (m, 5H), 7.89-
8.08 (m, 3H). 
6-Nitro-2,3-diphenylquinoxaline  
Light brown solid, IR (KBr, cm-1): 3433, 3328, 3055, 
1658, 1521, 1434, 1398, 1337. 1H NMR (CDCl3, 300 MHz): 
7.30-7.45 (m, 6H), 7.95 (d, 4H), 8.25 (d, 1H), 8.54 (d, 1H), 
9.08 (s, 1H). 
2,3-Bis(4-methoxyphenyl)quinoxaline   
White solid, IR (KBr, cm-1): 3054, 2926, 2871, 2349, 
1743, 1441. 1H NMR (CDCl3, 300 MHz): 3.85 (s, 6H), 6.89 
(d, 4H), 7.5 (d, 4H), 7.74 (q, 2H), 8.14 (q, 2H). 
2,3-Bis(4-methoxyphenyl)-6-methylquinoxaline   
Light yellow solid, IR (KBr, cm-1): 3054, 2922, 1955, 
1810, 1735, 1614. 1H NMR (CDCl3, 300 MHz): 2.61 (s, 3H), 
3.84 (s, 6H), 6.88 (d, 4H), 7.48 (d, 4H), 7.56 (d, 1H), 7.91 (s, 
1H), 8.03-8.0 (d, 1H). 
2,3-Bis(4-methoxyphenyl)-6-nitroquinoxaline  
Yellowish brown solid, IR (KBr  ¸cm-1): 3055, 3027, 1950, 
1659, 1540, 1477. 1H NMR (CDCl3, 300 MHz): 3.73 (s, 6H), 
6.98 (m, 4H), 7.56 (m, 4H), 8.24 (d, 1H), 8.49 (d, 1H), 9.1 
(d, 1H). 
Acenaphtho[1,2-b]quinoxaline  
Yellow solid, IR (KBr, cm-1): 3051, 2926, 1613, 1588, 
1528, 1497, 1418, 1343. 1H NMR (CDCl3, 300 MHz): 8.37-
8.40 (m, 2H), 8.18-8.21 (m, 2H), 8.05-8.08 (m, 2H), 7.78-
7.83 (m, 2H), 7.73-7.76 (m, 2H). 
9-Methylacenaphtho[1,2-b]quinoxaline  
Light Brown solid, IR (KBr, cm-1): 3051, 2909, 2861, 
1719, 1613, 1585, 1483, 1419. 1H NMR (CDCl3, 300 MHz): 
2.56 (s, 3H), 7.49 (d, 1H, Ar-H), 7.70 (t, 2H, Ar-H), 7.88 (s, 
1H, Ar-H), 7.94 (d, 2H, Ar-H), 7.99 (d, 1H, Ar-H), 8.27 (t, 
2H, Ar-H). 
Reusability of the catalyst 
At the end of the reaction, the catalyst could be 
successfully recovered by a simple filtration. The removed 
catalyst was washed with chloroform, dried at 80 ºC for 1 h 
and reused up to four times in the others reactions without 
appreciable reduction in the catalytic activity. 
 
CONCLUSIONS 
In conclusion, an efficient catalytic method for the 
synthesis of quinoxaline derivatives using sulfuric acid 
adsorbed on silica gel as catalyst in ethylene glycol at room 
temperature is reported. The catalyst can be reused after a 
simple work-up, with a gradual decline of its activity being 
observed.  
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